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Does increasing the number of cores of prostate biopsy 
improve diagnostic accuracy? Indications and morbidity 
Kapasi F, Chandrasekar P, Barber C, Samman R,  
Potluri B and Virdi J. 
 
Methods 
A study was conducted on accurate data maintained on 400 
patients who underwent transrectal ultrasound (TRUS) guided 
prostate biopsy. Patients were divided into three groups 
depending on the number of cores and each group was 
subdivided into two based on the PSA level (PSA<20 & 
PSA>20).  TRUS biopsy procedure was carried out using B and 
K medical ultrasound scanner no. 2002 (Panther Unit) using 
Biplanor rectal probe (8551). An 18G, 20cm biopsy needle 
(Biopty gun) was used.  
Intravenous Gentamicin 120mg, Metronidazole 500mg 
suppository given at the time of procedure, followed by oral 
Ofloxacin 400mg for three days were routinely used as antibiotic 
prophylaxis.The usual method of collection of the prostatic 
biopsy specimen is depositing it into a formalin pot directly from 
the biopsy needle; this leads to fragmentation of the specimen 
giving unsatisfactory results. 
We have developed a new technique for the collection of biopsy 
specimen. In our method, the specimen from the needle is 
mounted onto a formalin soaked sponge (figure 1). The sponge is 
then secured in a small cartridge, which is locked and deposited 
into the formalin pot (figure 2). By this method all specimens are 
kept intact and delivered safely to the pathology department. This 
gives pathologists accurate numbers of cores, which are easy to 
process and adds to reduction in preparation time. 
Introduction & Objectives 
Transrectal ultrasound guided biopsy is the standard procedure 
for detecting prostate cancers. It is uncertain how many cores are 
needed to optimise the detection of these cancers. The aim of this 
study was to compare the diagnostic accuracy of Prostatic 
carcinoma relating to the number of cores of prostate biopsy and 
its associated morbidity. 
The cancer detection rate for patients with a PSA of less than 20 
is not significantly improved if the number of cores taken is 
increased from 6-7 to 8-9, 0.2>p<0.25 (1 tailed t-test); however, 
increasing cores from 8-9 to >10 and from 6-7 to >10 does 
significantly increase the detection rate, p valves of <0.025 and 
<0.005. There is no difference in the detection rate with the 
increase in number of core biopsies when the PSA is greater than 
20. Mean detection rate 0.71, 95% CI = 0.57 to 0.85. 
Complications 
The complications were: clot retention in one (0.25%), rectal 
bleed in two (0.5%) and urethral bleed in two (0.5%). These were 
only observed in patients who underwent more than 10 core 
biopsies. None developed septicaemia requiring emergency 
admission. 
Results and Conclusions 
1.  Diagnostic accuracy improved from 14% to 34% by 
increasing the number of cores from six to twelve when PSA is 
less than <20 particularly inT1c prostatic cancer, however, it did 
not improve when the PSA was >20 and >T1 disease. 
2.  In this study the complication relating to prostatic biopsy was 
1.25%, which was recorded in patients who had more than 10 
cores biopsy. In spite of this, to increase diagnostic accuracy in 
T1c disease we recommend more than 10 core biopsy. 
3.  Our antibiotic regime is effective in protecting episodes of 
septicaemia.  
4.  The method of collection of specimen has distinct advantages 
in preserving specimens and increasing speed of processing 
Anorectal dysfunction after 3-D conformal radiotherapy for 
localised  prostate cancer  
Dickon Hayne, Nula Allen, Dan Ashdown, Amanda Mellon,  
John Glaholm, Mike Foster 
Good Hope Hospital, Birmingham,   
 
Introduction: 
Previous work (Ref 1, 2) has shown a very high incidence of 
anorectal side effects with associated changes on anorectal 
physiology following conventional radiotherapy for localised 
prostate cancer (CaP). We report early results on the first 
prospective study aiming to identify symptoms and quantify 
anorectal dysfunction after 3-D conformal radiotherapy (3D-
CRT) for CaP. 
Patients & methods: 
Ethical approval was obtained from the North Birmingham 
Regional Ethics Committee. Twelve men (median age 66 years) 
with CaP were treated with 3D-CRT using a hypofractionated 
schedule of 55Gy in 20 fractions over 4 weeks. All patients 
completed incontinence/proctitis symptom scores, endo-anal 
ultrasonography and anorectal physiological studies before and 6 
weeks after RT. Results were expressed as medians and ranges 
and compared using a Wilcoxon signed rank test.  
Results: 
Incontinence scores: 0 (0-5) v 0.5 (0-6) (p=NS) and proctitis 
scores: 0 (0-2) v 1.5 (0-5) (p<0.05), increased 6 weeks post-3D-
CRT. There was no statistically significant change in anal canal 
manometry, rectal volumes, anal/rectal electrical sensitivity, 
pudendal terminal motor latencies or the sonographic appearance 
of the sphincter on endo-anal ultrasound. 
Conclusions: 
Proctitis was seen six weeks after 3D-CRT. Changes in 
incontinence scores and anorectal physiology were not 
demonstrated to a statistically significant degree. Though 
numbers are still small, comparison to previous work suggests 
that anorectal disturbance is less after 3D-CRT than conventional 
RT. Ongoing recruitment to this study should confirm this 
finding. However, future dose escalation is planned and may 
result in increased anorectal morbidity. 
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PSA RESULTS FOR BRACHYTHERAPY IN THE UK 
WITH FOLLOW UP OVER FIVE YEARS 
Sooriakumaran P, Henderson A, Langley SEM, Laing RW 
St. Luke’s Cancer Centre, Royal Surrey County Hospital, 
Guildford, GU2 7XX 
 
Introduction 
We report early outcome data for patients who underwent 
prostate brachytherapy (BXT) using stranded I-125 implant 
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Patients and Methods 
We have prospectively collected data on PSA outcomes on all 
482 patients we have treated to date. We report biochemical 
outcomes for the first 300 of these patients with a median follow 
up of 31m; range 16-66m. Patients were classified into low 
(49%), intermediate (37%), and high (14%) risk categories based 
on their Gleason sum, presenting PSA, and clinical stage. Patients 
received either BXT alone (32%), BXT with 3m neoadjuvant 
androgen deprivation (NAAD) (46%), or a combination of 3m 
NAAD, 45 Gy EBRT, and BXT (22%). 
Results 
Prostate cancer survival was 100%; no deaths occurred with 
rising PSA. 16 patients (5.3%) experienced biochemical evidence 
of treatment failure (ASTRO definitio). Actuarial PSA free 
survival for all patients was 95% at 66m. There was no 
significant difference in actuarial survival in hormone-naïve 
(95%) versus hormone-treated (94%) patients or between patients 
in different risk categories (low risk- 94%; intermediate risk- 
95%; high risk- 98%). At 3yr median PSA was 0.2 for all patients 
(n=81); 0.3 for low risk (n=36), 0.2 for intermediate risk (n=29), 
and 0.1 for high risk (n=16) groups. There was no significant 
difference in median PSA at 3yr in hormone-naïve (0.4) (n=27) 
versus hormone-treated (0.2) (n=54) patients. 65/81 (80%) 
patients had a 3yr PSA ≤0.5. 
Conclusion 
These early results demonstrate the effectiveness of 
brachytherapy in the treatment of early prostate cancer and 
suggest that the excellent results achieved in the USA are 
reproducible in the UK. 
 
 
Effects of prostate brachytherapy on erectile function- 
prospective UK data 
Sooriakumaran P,  Henderson A, Langley SEM, Laing RW. 
St Luke’s Cancer Centre, Royal Surrey County Hospital, 
Guildford, GU2 7XX 
 
Introduction 
We assess the effect of brachytherapy on potency in a 
prospective, patient administered questionnaire study. 
Methods 
Patients completed the International Index of Erectile Function 
(IIEF-5) prior to brachytherapy and at 6 weeks, 3,6,9,12,18 and 
24 months post implant. Men with an IIEF-5 score of <12/25 
were considered to have moderate or worse ED and were classed 
as impotent.   
Results 
180 patients completed baseline and >1 postimplant IIEF-5 
questionnaire; 45% (n=81) were potent pre-implant.  80% of 
potent patients maintained potency at last follow up (mean FU 
15m). For pre-implant potent patients, erectile function generally 
improved over time: 6wk-48%; 3m-64%; 6m-53%; 9m-63%; 
12m-67%; 18m-61%; 24m-78%. 
Conclusion 
Erectile function generally improves with time post-
brachytherapy with >75% pre-implant potent patients 
maintaining potency at 24 months. This compares favourably 
with surgery, radiotherapy, and cryotherapy for the treatment of 






Thromboprophylaxis for Radical Prostatectomy: A 
Comparative Analysis of Present Practice between the USA, 
the UK and Ireland. 
David J. Galvin, David Mulvin and David M. Quinlan 
Department of Urology, St. Vincents’ University Hospital, 
University College Dublin, Elm Park, Dublin 4, Ireland. 
 
Introduction 
A clinical dilemma exists in the management of patients 
undergoing radical prostatectomy whereby measures taken to 
reduce the risk of thrombotic events may adversely affect efforts 
to limit blood loss. No consensus exists in the literature on the 
ideal management of thromboprophylaxis in these patients. Our 
aim is to examine and compare current thromboprophylactic 
policy and practice in centres performing radical prostatectomy. 
Methods 
A questionnaire was forwarded to all urology residency 
programmes in Ireland, the United Kingdom and the United 
States, regarding their current practice with respect to 
thromboprophylaxis in radical prostatectomy. Completed 
questionnaires were returned by fax, and the data entered into a 
computer database. 
Results 
An overall response rate of 60% was achieved. The 
questionnaires demonstrated a significant difference in clinical 
practice between Urologists in the United States and the United 
Kingdom. Just 24% of American Urologists use pharmacological 
thromboprophylaxis in contrast to 100% of British Urologists, yet 
there is no difference in the incidence of reported thrombotic 
events. There was no difference in the use of non-
pharmacological thromboprophylaxis.  Units performing the 
largest number of radical prostatectomies do not use 
pharmacological thromboprophylaxis, whereas units doing fewer 
procedures do. 
Conclusion 
This study, which examines current clinical practice, 
demonstrates that the units performing the greatest number of 
radical prostatectomies do not use thromboprophylaxis, although 
the literature remains divided on this strategy. 
 
 
Obesity, prior lower abdominal surgery and laparoscopic 
radical prostatectomy. 
T. Gianduzzo, C. Chang and C. Eden 
North Hampshire Hospital, Basingstoke. 
 
Introduction:  
Obesity and previous lower abdominal surgery are both relative 
contra-indications to laparoscopic pelvic surgery. However, 
patients exhibiting these features may gain more than most from 
a laparoscopic approach due to the additional difficulty 
encountered in operating on them by open surgery (Chang, 2004; 
Katz, 2002). Increased experience with laparoscopic radical 
prostatectomy (LRP) has allowed us to test this hypothesis. 
Materials and Methods:  
350 cases of LRP were performed from March 2000 to July 004, 
111 using a transperitoneal and 239 using an extraperitoneal 
route. 20 patients were classified as obese (>100 kg). 97 had 
lower abdominal scars due to unilateral hernia repair (n=48), 
bilateral hernia repair (n=14), appendisectomy (n=31) or other 
procedures (n=4). Peri-operative and post-operative parameters 
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Results:  
Patients’ age, PSA, Gleason score, clinical stage and prostate 
volume were similar. 
Non-obese & obese patients’ mean values for operating time=195 
& 183 min, blood loss=261 & 263 ml, complications=3.3% & 
5.0%, hospital stay=3.1 & 3.9 nights, + margins=15% & 15% and 
biochemical recurrence=2.0 & 5.0%. 
Mean values for patients without and with lower abdominal scars 
for operating time=175 & 185 min, blood loss=243 & 240 ml, 
complications=4.4% & 2.9%, hospital stay=2.7 & 3.1 nights, + 
margins=14% & 15% and biochemical recurrence=2.2 & 4.0%. 
Conclusion:  
Neither obesity nor a lower abdominal scar influenced any of the 
variables (p>0.05) listed above. Obesity and previous lower 
abdominal surgery do not appear to have the same negative 
impact on blood loss and operating time during LRP as has been 
reported during open radical prostatectomy (ORP). Obese 
patients and those with lower abdominal scars might be better 
served by LRP than by ORP. 
 
 
Prostate Cancer Screening in Ireland: A feasibility study 
Galvin DJ, Rea D, McDermott TED, Grainger R, Butler M, 
Thornhill JA. 
Adelaide and Meath Hospital Incorporating the National 
Children’s Hospital, Tallaght, Dublin 24, Ireland. 
 
Introduction 
The true prevalence of prostate cancer is unknown in Ireland. Its 
detection is currently low as no national screening programme 
exists. Randomised prostate cancer screening studies have 
demonstrated reductions in cancer-specific mortality. In order to 
assess the validity and feasibility of prostate cancer screening in 
Ireland, we developed two pilot prostate cancer screening 
programmes at our Institution. 
Methods 
The first study invited men aged 18 to 66 years from a 
nationwide financial institution to attend for Men’s Health 
Screening. The second study invited men from the general 
population between 40 and 70 years to attend for prostate cancer 
screening. All men had a PSA taken and a DRE performed by a 
guided prostate biopsy (six-core) were a PSA > 4 ng/ml or an 
abnormal DRE. 
Results 
Comparison of Both Prostate Cancer Screening Trials 
 STUDY 1 STUDY 2 
Total Subjects 677 969 
n 468 969 
Mean Age 50.9 years 55.1 years 
Mean PSA 1.2 ng/ml 1.35 ng/ml 
Abnormal DRE 26 (5.5%) 39 (4%) 
PSA >4ng/ml 12 (2.56%) 44 (4.5%) 
TRUS Bx. 9 (1.9%) 34 (3.5%) 
Cancer 
Detection 2 (0.42%) 13 (1.3%) 
Radiotherapy 0 8 
RRP 2 5 
 
Conclusions 
These two studies demonstrate the feasibility of prostate cancer 
screening in Ireland. If screening is to be introduced on a national 
basis, there are significant personnel and resource implications at 
both primary care and hospital settings. 
 
 
Men’s preferences for two different endocrine therapies in 
the treatment of prostate cancer 
Jenkins, VA. , Edginton TL, Fallowfield, LJ 
Brighton & Sussex Medical School, University of Sussex 
 
Introduction 
Anti-androgen therapy and Lutenising Hormone Releasing 
Hormone (LHRHa) have equivalent efficacy in the treatment of 
locally advanced prostate cancer (Iversen et al 2000, J Urol, 164: 
1579 & See et al. 2002, J Urol, 168, 429-435), yet most clinicians 
prescribe LHRHa therapy.  Both of these treatments have 
different side effect profiles impacting on men’s quality of life. 
They are also administered differently either by injection or 
tablets. Our survey examined preferences of healthy men and 
reasons for these when presented with the profiles of both drugs. 
Materials and Methods 
Scenarios describing side effect profiles of Drug A (LHRHa 
treatment) and Drug B (anti-androgen therapy) were constructed 
and modified following expert feedback. A representative sample 
of 180 men without prostate cancer (68% over 65 years of age), 
read the scenarios and were asked to choose which drug 
treatment they would prefer, with a reason for their choice. Also 
participants stated the degree to which they wanted to avoid side 
effects specific to each drug. 
Results 
156/180 (86%) men choose anti-androgen therapy, the majority 
115/156 wishing to avoid the side effects associated with 
LHRHa. 12 men chose LHRHa of whom 9/12 cited the method 
of administration as the main reason for their choice. 12 men 
could not decide. Examining which side effects men most wanted 
to avoid experiencing included, in descending order of 
importance, risk of fractures (85%), reduced physical strength 
(76%), hot flushes (56%), decreased sexual interest (56%), 
impotence (51%), breast enlargement (17%) and breast 
tenderness (13%). This did not differ significantly according to 
age, marital or socioeconomic status. 
Conclusion 
Although this study has the limitations associated with 
hypothetical research in a non-clinical group, it showed a 
compelling preference for anti-androgen therapy over LHRHa. 
Findings might encourage clinicians to present real patients with 
choices in treatment when efficacy is equivalent and discuss side 
effects that will impact on quality of life. 
 
 
Who should perform trans-rectal ultrasound (TRUS) guided 
biopsy of the prostate: Urologists or Radiologists? 
James A Forster, Jonathan Krell, Philip M.T. Weston, Tony J 
Browning, Kanwar Gill* and Subramanian Kanaga-Sundaram,  
Departments of Urology and Radiology*, Pinderfields General 
Hospital, Mid Yorkshire Hospitals NHS Trust,  
Aberford Road, Wakefield, West Yorkshire WF1 4DG.  
 
Introduction:  
Trans-rectal ultrasound guided biopsy of the prostate is a 
common procedure, and its use is increasing with the advent of 
PSA. Screening for prostate cancer in the US has lead to over one 
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million prostate biopsies being taken there every year. 
Traditionally in the UK radiology departments have provided this 
service. The pressures of cancer waiting times and increasing 
work-load have caused radiology departments difficulties in 
providing optimal service. The decision as to whether urologists 
or radiologists perform the procedure varies according to local 
policies and expertise. Although there is a good deal of data 
published on technique, results and complications of the 
procedure, to our knowledge there is no data comparing the 
results gained by urology and radiology departments. That is the 
purpose of this study. 
Materials and methods:  
Data of TRUS-guided prostate biopsy performed over a twelve 
month period commencing in January 2003 were retrospectively 
analysed. The indication for the procedure including PSA value, 
speciality of operator, number and position of cores and the 
histology results were analysed.  The positive and negative 
predictive values of DRE, PSA and TRUS for each operator that 
resulted in a diagnosis of prostate cancer were calculated.  
Results:  
A total of 414 procedures were performed in the study period, 
283 by consultant urologists and the rest by a radiologist. The 
cohort of patients in each group had similar PSA levels. Overall 
175 biopsies were positive for prostate cancer (42%). The 
urologists had a positive biopsy rate of 41%; the radiologist had a 
positive biopsy rate of 44%. There was no statistical significance 
between the two groups (p=0.574). The positive predictive values 
of DRE performed by urologists were 59%, 75% and 37%. The 
negative predictive values of DRE performed by urologists were 
67%, 60% and 81%. An elevated PSA (>4.0) gave a positive 
predictive value of 45%; a normal PSA (<4.1) gave a negative 
predictive value of 89%. Positive predictive value of TRUS was 
77%, 67% and 50% for the urologists, and 52% for the 
radiologist.  
Conclusion:  
TRUS-guided prostate biopsy has a comparable yield of detecting 
cancer when performed by urologists and radiologists. With 
increasing pressure on waiting time and the introduction of office 
urology, in the future it is appropriate that this procedure is 
performed by adequately trained urologists. Our findings show 
that our department has similar predictive values in methods used 
to diagnose prostate cancer compared with national and 
internationally published data. 
 
 
Cryotherapy for prostate cancer: Initial experience 
J Cresswell, M Choudhary, S Asterling and D Greene 
Dept of Urology, Sunderland Royal Hospital, Sunderland, UK 
 
Introduction 
The development of cryotherapy for localised prostate cancer 
provides a potentially curative option for patients with primary or 
recurrent disease, with reduced morbidity. We report the first 31 
consecutive patients treated at our centre. 
Patients and Methods 
Data were collected prospectively for all patients. In 23 patients, 
cryotherapy was used as primary treatment, and as salvage 
therapy in 7 previously treated with radiotherapy (6 EBRT, 1 
brachytherapy), and 1 following hormone treatment alone. All 
had biopsy proven prostate cancer and negative bone scans. 
Gleason grade was 7 or less in 25 patients and >7 in 5 patients 
(grade not recorded for 1 patient). Median PSA for primary 
treatment was 9.1µg/L (range 1.6 – 25.4µg/L) and 12.6µg/L 
(range 2.5 – 20.1µg/L) for salvage cases. A single urologist 
performed all treatments using an argon-based cryotherapy 
system with transrectal ultrasound. Median operative time was 
146 mins (range 109 – 231 mins). A suprapubic catheter was 
placed intra-operatively and remained in place for 2 weeks post-
operatively. 
Results  
All patients tolerated the procedures well and median hospital 
stay was 3 days. Median follow up time was 3 months (range 2 
wks – 1 year). Of 23 patients with > 3 months follow-up, 17 
reached a PSA nadir of <0.5µg/L at 3 months. Of the patients 
undergoing primary treatment 5 failed to reach this nadir. Three 
out of 4 salvage treatments reached a PSA nadir of <0.5µg/L at 3 
months. Complications included 3 cases of urinary retention after 
removal of suprapubic catheter with 2 patients requiring 
subsequent TURP. Six patients developed urinary incontinence 
that persisted for a median of 3 months and all 11 patients with 
normal erections preoperatively, developed erectile dysfunction. 
No patient developed a fistula.  
Conclusion 
Preliminary results suggest that cryotherapy offers a safe and 
effective alternative for the primary and secondary treatment of 
prostate cancer. Advantages include shorter hospital stay and 
lower morbidity compared to radical surgery. Long-term follow-
up is required to assess the durability of response and therefore 
probability of cure. 
 
 
Prostate cancer in the over eighties - are we too aggressive? 
A. Mampitiya, D. Wijewardena, D.N. Wood, S.S. Gujral 
Harold Wood Hospital, Barking, Havering and Redbridge NHS 
Trust, Romford, Essex 
 
Introduction: 
Post-mortem studies in octogenarians reveal 60-80% prevalence 
of prostate adenocarcinoma(CaP) (Breslow N et al Int J Cancer 
1977; 20(5):680-8). Diagnosis of CaP in this age group does not 
significantly reduce life expectancy (Welch HG et al Ann Intern 
Med 1996; 124(6):577-84). However, there is still pressure to 
diagnose and patients with CaP. Referral patterns and outcomes 
in these men were assessed. 
Patients and Methods: 
Case notes of octogenarians diagnosed with CaP at a single unit 
in 2001 were reviewed. Referral patterns, diagnostic criteria and 
outcomes were recorded. 
Results: 
143 octogenarians were referred for TRUS biopsies (35% of total 
biopsy referrals): 63% by GPs for raised PSA (9 to 53ng/ml), 
30% from the “LUTS” clinic (abnormal DRE) and 6% for 
histological confirmation in clinically advanced disease. 77 had 
biopsy proven CaP.  GPs did a DRE in 50%  - their findings 
showed excellent correlation with those of urologists.  GP PSA 
indications were screening (42%), simple LUTS (52%) and  back 
pain (6%). 57% had T2 staging. 61% had bone scans - only 12% 
being positive (all with T3+ disease). 75% had low to moderate 
Gleason scores. Following counselling, 91% opted for immediate 
hormonal manipulation, 8% watchful waiting and 1 patient chose 
radical radiotherapy. At two years, there was a 30% recorded 
mortality, only 6% were CaP related. 
Conclusion 
Despite a known high prevalence of indolent CaP in 
octogenarians, many have PSA tests performed in the community 
which could sensibly be avoided if prior counseling were 
employed. Abnormal results lead to anxiety (often fuelled by the 
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At this stage even with comprehensive counselling many of these 
men opt for active therapy on diagnosis rather than watchful 
waiting despite little evidence regarding survival or quality of life 
benefits. National guidelines for management of these men 
should be developed. 
 
 
Patient satisfaction with Uro-oncology nurse specialists —A 
questionnaire survey 
J. Masood, H. Forristal, R. Cornes, M. T. Vandal, S.S. Gujral 
Department of Urology, Harold Wood Hospital, Romford, UK 
 
Introduction 
Specialist nurses have an established role in the management of 
Urological cancer in helping patients to understand their disease 
and treatment options, and in offering counselling and emotional 
support. There is evidence to suggest that patients who see the 
nurse specialist express more satisfaction and have less anxiety 
than those who see either a male or female junior doctor 
(Hammond C. Dissertation, University of Surrey, 1994). Other 
studies have found that the specialist nurses’ clinical expertise 
compared favourably with that of other clinicians (Garvican et 
al., BMJ. 1998; 316 (7136): 976-7). The nurse specialists also 
provide unbiased counselling. This study describes patient 
satisfaction with Uro-oncology nurse specialists and their nurse 
led clinics. 
Methods 
One hundred, 15 point, patient satisfaction questionnaires were 
sent to new and existing patients with urological cancer who had 
been randomly identified by the Uro-oncology nurse specialist. 
The questions were mainly concerned with the provision of 
information to patients and with the satisfaction of the nurse 
specialist service. 
Results 
70 patients completed and returned the questionnaires. 73% of 
patients were over 70 years of age. 88% of patients were male. 
94% of patients were Caucasian in background. 11% of patients 
saw the nurse specialist at diagnosis and 17% immediately after 
diagnosis. 76% found this consultation beneficial. 47% of 
patients felt it would be more beneficial to see the clinical nurse 
specialist before they saw the consultant. 79% of patients 
received information on their disease and treatment in verbal 
format, 15% received both verbal and written information and 
1% received written information only. 55% of the patients 
received this information from the nurse specialist.  81% of these 
patients found the information very useful and 84% of patients 
found this information easy to understand. 90% of patients said 
they had adequate opportunity to ask questions and raise concerns 
with the nurse specialist and 93% were given a contact number 










Difficult to contact 2 Unhelpful 0 
Not enough contact 1 Considerate 42 
Crucial to my 
recovery 
10 Supportive 39 
Promoted 
independence 
2 Professional 46 
Easy to contact 32 Condescending 0 
Bossy 0 Rushed 0 
Friendly 51 Invaluable 25 
Wonderful 12 Poor 1 
Adequate 1 Informative 39 
Sensitive 24 Irrelevant 0 
Table 1: Outlines words, which describe the care patients 
received from the Uro-oncology nurse specialist 
Conclusion 
Patients found contact with the Uro-oncology nurse specialist 
supportive, informative and beneficial to their treatment. Patients 
seem undecided whether they should see the nurse specialist 
before or after the consultant. We feel that raising the profile of 
the Uro-oncology nurse specialist would be beneficial to patient 
treatment and care.  
 
 
www; the wild, wild web: Internet usage in patients with 
urological cancer in 2004 
J. Masood, J. Shahzad, T.A. Ghazali, M. T. Vandal, S.S. Gujral 




The Internet has an enormous number of health related web sites 
and can be a valuable source of medical information to the public 
and health professionals. Patients can independently search the 
Internet to learn about their illness and treatment options. There is 
evidence to suggest that there is a better outcome in patients who 
are well informed. However, of concern, is the quality of some 
information available on the “Net”. Some Internet sites may 
contain erroneous information on cancer that can pose problems. 
We assess Internet usage and its benefit amongst our patients 
with urological cancer. We also assess if patients are advised to 
visit particular sites on the “Net” by health professionals 
Methods 
All patients attending our outpatient clinic in 2004 with any type 
of urological cancer were asked to complete a 10-point 
questionnaire. We assessed their use of the Internet to gain 
information about their cancer and if they were advised to look at 
any web sites by health professionals. Patients were asked if they 
could name any of the web sites they may have visited, if these 
sites were useful in improving their understanding of the disease 
and whether, the information they gathered helped them to make 
a more informed decision about the further management of their 
cancer.  
Results 
A total of 170 completed questionnaires were evaluated. These 
included 139 males (mean age 69years; range 52 - 86years) and 
31 females (mean age 71 years; range 62 -81 years) in the cohort. 
98% of patients said they had discussed their cancer with a health 
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professional. Only 42 patients (24%) had direct access to the 
Internet. Of the others, 36% had access via friends/family. Only 
11 patients (6%) were advised to visit specific websites and all 
were advised to do so by the Uro-oncology nurse specialists. 
Only 20 patients (11%) in total had visited urology cancer web 
sites. Only 2 patients could recall the web sites they had visited. 
All patients who visited websites found them either “useful” or 
“very useful”, and stated learning about staging, prognosis of 
their disease and complications of surgery and alternative 
treatment therapies. Not surprisingly, younger patients, males, 
patients of higher social class and those with direct access to a 
computer were more likely to use the Internet 
Conclusion 
We found that only 11% of patients with urological cancer in our 
cohort have used the Internet, and they found this resource very 
useful. Although Internet usage amongst the general urological 
patient population appears to be on the increase, (Hellawell et al., 
BJU Int. 2000; 86(3): 191-4) patients with cancer tend to be older 
and may not have the facilities or the know-how to use the 
Internet. Health professionals are counselling too few patients 
about urological cancer websites. Urologists and nurse specialists 
should be made aware of the need to familiarize themselves with 
urological websites. Evidence that computer generated 
information systems are superior to written and verbal 
information exists (Bulmer et al., BJU Int. 2001; 88(6): 532-5).  
We advocate visual (using the internet during consultation) and 
verbal counselling of these patients. Patients can then be directed 
to high-quality sites so that they can educate themselves about 
their cancer and avoid misleading websites. 
 
 
CYP1B1 expression is higher in the peripheral zone compared 
to the transition zone: a difference underlying zonal 
susceptibility to prostate adenocarcinoma? 
Narasimhan Ragavan1,2,4, Rebecca Hewitt4, Andrew C. Hindley2, 
Caroline M. Nicholson3, Shyam S. Matanhelia1,  
Francis L. Martin4 
Departments of Urology1, Oncology2 and Pathology3, Lancashire 
Teaching Hospitals NHS Trust. Department of Biological 
Sciences4, Lancaster University, Lancaster. UK 
 
Introduction  
The prostate is a composite organ divided into zones.  Prostate 
adenocarcinoma (CaP) mostly occurs in the peripheral zone.  
Cytochrome P-450 (CYP) isoenzymes are constitutively 
expressed and inducible enzymes, many of which (e.g. CYP1A1, 
CYP1A2 and CYP1B1 isoforms) are involved in hormone and 
carcinogen hydroxylation. 
Aim 
To assess variations in CYP expression in the prostate on an intra- 
(peripheral zone Vs. transition zone) and inter-individual basis. 
Materials and Methods  
Human prostates (n=24) were obtained, with ethical approval, 
from radical retropubic prostatectomies.  Study participants 
exhibited low PSA (< 20 µg/l serum) and low volume of disease 
(< two/eight core biopsies positive for CaP).  Following 
resection, tissue sets consisting of peripheral zone and transition 
zone were isolated from a lobe pre-operatively identified as 
negative for CaP.  A histopathologist always examined adjacent 
tissue.  Real-time RT-PCR was employed to quantitatively 
examine CYP1A1, CYP1A2 and CYP1B1. 
Results 
CYP1A1 mRNA transcripts were detected in either or both zones 
of twenty tissue sets (in seven cases, in both zones) and were 
undetectable in four others.  In eleven tissue sets, higher levels of 
CYP1A1 expression were observed in the peripheral zone 
compared to the transition zone (maximum six-fold difference) 
whereas in nine other tissue sets this relationship (maximum 2.5-
fold difference) was reversed.  CYP1A2, although detectable in 
twelve tissue sets, was not quantifiably expressed.  CYP1B1 
expression was detected in both zones of all tissue sets examined.  
Inter-individual variation in CYP1B1 expression levels in 
peripheral zone (five-fold differences) and transition zone (ten-
fold differences) were noted.  In sixteen out of seventeen tissue 
sets found to be cancer free, CYP1B1 expression was found to be 
two- to fifty-fold higher in the peripheral zone compared to the 
transition zone; in the remaining tissue set an equal level of gene 
expression was detected in both zones.  In the tissue sets 
containing CaP, CYP1B1 expression was higher in the cancerous 
zone (be it peripheral or transition) in five of six cases; in another 
tissue set containing PIN, an equal level of gene expression was 
again detected in both zones.  Immunohistochemistry clearly 
demonstrated a nuclear staining pattern for CYP1B1 in epithelial 
and stromal cells of both zones; the staining density of this 
protein was markedly elevated in cancerous tissue. 
Discussion  
CYP1B1 preferentially catalyses the 4-hydroxylation of 17β-
oestradiol, metabolically activates exogenous pro-carcinogens 
and inactivates anticancer agents.  Future studies will investigate 
whether CYP1B1 may be employed as a target either for 
chemoprevention strategies or treatment of clinically invasive 
disease. 
 
The Economic Consequences of Prostate Cancer in the UK. 
N Ragavan, VK Sangar, SS Matanhelia, ME Watson, RA Blades 
Department of Urology, Lancashire Teaching Hospitals NHS 
Trust, Preston, UK 
 
Introduction  
The incidence of prostate cancer is increasing due to heightened 
patient awareness and the availability of PSA testing. There is 
little data available on the impact of this disease on the UK health 
care economy. Availability of such data is necessary for the 
adequate direction of resources. The aim of this study was to 
assess the economic impact of prostate cancer  
Method 
All the new prostate cancers diagnosed in 2001-2002 were 
identified from BAUS section of oncology database. 
Corresponding patients were identified from the local hospital 
database to facilitate calculation of indirect costs. 
The Total Cost (TC) of diagnosing, treating and following up 
patients for five years was estimated as the sum of Direct Costs 
(DC) (NHS) and Indirect Costs (IC) (loss of earnings).  
Results  
In the period studied there were 15099 newly diagnosed prostate 
cancers (mean age 72.3y) The treatments for these prostate 
cancer patients were radical prostatectomy (RRP) (n=1506), 
radical radiotherapy (RRT) (n=2735), hormone therapy (n=7127) 
and chemotherapy (n=18). There were 1320 patients for whom no 
treatment was available from the database so they were assumed 
to be on active monitoring. 1065 patients were entirely excluded 
from the calculation as the treatments they received were not 
clear. 
The TC for the diagnosis, treatment and five-year follow up of 
prostate cancer patients diagnosed during 2001 – 2002 was 
estimated at £ 92.74 million  
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Chemo - 0.02, TURP1.9). The expenditure on hormonal therapy 
accounted for over two-thirds of the TC. The TC of radical 
radiotherapy and radical prostatectomy were similar, but almost 
one and half times more patients were treated with radical 
radiotherapy than with prostatectomy. The average cost of 
treatment of a prostate cancer patient was £ 7294. 
The direct costs, which imply the burden directly borne by the 
National Health Service, form the greater proportion of the total 
cost (97.6%)  
Conclusion  
The management of prostate cancer has a significant impact on 
the health care budget. Cost effective treatment options without 
compromising the quality of care (e.g. orchidectomy) need to be 
revisited. 
 
Expression and Differential Modulation of Adiponectin 
Receptors in Prostate Cancer Cell Lines 
T Mistry1,2, E Karteris1, J Digby1, J Chen1, K Desai2, 
H.S. Randeva1 
1Biomedical Research Institute, Department of Biological 
Sciences, University of Warwick, Coventry, CV4 7AL, and 
2Department of Urology, University Hospitals Coventry and 




Adiponectin is an adipocytokine that has been shown to have 
anti-atherogenic and anti-inflammatory actions, and has been 
implicated in the pathogenesis of insulin-resistant states such as 
obesity and Type 2 diabetes mellitus. Adiponectin orchestrates its 
actions by activating two membrane receptors (adipo-R1/R2) that 
despite possessing a classic seven transmembrane structure, have 
characteristics distinct from any known G-protein receptor. 
Recent studies have shown that adiponectin levels are 
significantly decreased in women with endometrial and breast 
cancer, other hormone-dependent cancers. To date, little is known 
about the role of adiponectin receptors in prostate cancer, the 
progression of which is positively correlated with obesity and 
hyperinsulinaemic states. Therefore, we hypothesised that there 
might be a direct link between insulin-resistant states and prostate 
cancer, via adiponectin receptors. In this study we aim to 
investigate in detail the expression of adiponectin receptors in 
prostate cancer cell lines, and the influence of various hormones 
and growth factors on their expression.  
Materials and Methods 
Expression of adiponectin receptors was determined using RT-
PCR, sequencing analysis, Western blotting analysis and 
immunohistochemistry in two different cell prostate cancer cell 
lines, PC-3 (androgen independent) and LNCaP (androgen-
dependent). RT-PCR and Western blotting were also used to 
investigate the regulation of adiponectin receptor expression by 
various hormones and growth factors. 
Results  
Adipo-R1 and adipo-R2 were detected in both PC-3 and LNCaP 
cell lines at mRNA and protein level using RT-PCR and Western 
blotting. Immunohistochemical analysis confirmed membrane 
localisation of both receptors. Down-regulation of adipo-R1 was 
found in response to TNF-α and dexamethasone in the cell lines 
studied, whereas testosterone caused down-regulation of both 
receptors. Growth hormone and β-estradiol had no effect on 
receptor subtype expression. 
 
Conclusion 
In this study we demonstrate for the first time the expression of 
adiponectin receptors in prostate cancer cell lines, suggesting that 
adiponectin can exert effects at the prostate level, acting in an 
endocrine/paracrine manner. Furthermore, we provide novel 
evidence about the differential regulation of these receptors by 
hormones, steroids and glucocorticoids. Further studies are 
required to investigate the potential role of adiponectin and its 
receptors in the aetiopathogenesis of prostate cancer and its 
relationship to the hyperinsulinaemic state. 
 
 
Emergency bilateral orchidectomy –a life saving procedure in 
urological emergencies (apart from paraplegia) caused by 
carcinoma prostate 
Makarand V Khochikar 
Siddhi Vinayak Ganapati Cancer Hospital, Miraj (India) 
 
Introduction  
Acute paraplegia due to spinal cord compression in a case of 
metastatic prostate cancer is an oncological emergency. 
Usefulness of bilateral orchidectomy in this situation is very well 
proven. Disseminated Intravascular Coagulation (DIC), 
intractable hematuria, anuria due to ureteric obstruction, raised 
intracranial tension (ICT) with convulsions, acute breathlessness 
due to pulmonary metastasis are few other oncological 
emergencies in case of advanced /metastatic prostate cancer. 
Operative risk in these cases is very high. Effectiveness of 
bilateral orchidectomy in these situations is evaluated in this 
study. 
Materials and Methods  
During 1998-2004, 14 cases of advanced/metastatic prostate 
cancer with above-mentioned emergencies were dealt with. These 
were-disseminated intravascular coagulation (DIC)-7 cases, 
anuria due to ureteric obstruction-3 cases, raised ICT with 
convulsions –1case,acute breathlessness due extensive pulmonary 
metastsis-1 case and intractable hematuria –2 cases. Emergency 
bilateral orchidectomy was performed under local anaesthesia  in 
all these cases. 
Results  
Bilateral orchidectomy was found to be extremely effective in all 
these cases. DIC and intractable hematuria could turn to 
normalcy within 72 hours, ureteric obstruction could open up 
within 48 hours, breathlessness could revert to stable respiratory 
status over 72hours and raised ICT could normalize within 4 
days. 
Conclusion 
Advanced /metastatic prostatic cancer can manifest with 
oncological emergencies that need prompt /active treatment. 
Bilateral orchidectomy proves life saving in these situations, even 




An elevated PSA, which normalises does not exclude the 
presence of prostate cancer 
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Patients with an elevated prostate specific antigen (PSA) level are 
known to have an increased risk of harbouring prostate cancer 
(Stamey et al. N Engl J Med 1987; 317(15): 909-16). However, 
recent work has shown that a significant proportion of patients 
found to have an elevated PSA, will have a normal value if it is 
repeated (Eastham et al. JAMA 2003; 289(20): 2695-700). What 
is uncertain is how this relates to the presence of prostate cancer. 
The current study looks to address this issue by determining the 
incidence of cancer in patients who have an elevated referral 
PSA, which subsequently falls to within the normal range.  
Materials and Methods:  
A prospective study was conducted in men undergoing a prostate 
biopsy following the finding of an elevated PSA, according to 
their age-specific reference range (40-49 years 0-2.5ng/ml, 50-59 
years 0-3.5ng/ml, 60-69 years 0-4ng/ml, 70-79 0-6.5ng/ml). Prior 
to the procedure a urological history, urine dipstick and repeat 
PSA test were performed and the results of a prostate 
examination recorded. The referral and repeat PSA value were 
then compared and related to the subsequent histology.  
Results:  
21 of the 160 (13%) study patients had a repeat PSA level which 
had fallen back to within the normal age-specific reference range. 
5 of these 21 (24%) patients were diagnosed with prostate cancer, 
3 of these patients had a suspicious digital rectal examination 
(DRE) before the procedure but 2 had a normal prostate 
examination.  
Conclusion:  
This study clearly demonstrates that just because the PSA 
normalises before the biopsy procedure does not mean that the 
presence of prostate cancer can be excluded, even if the prostate 
feels benign.  
 
 
How are prostate biopsies performed in the United Kingdom 
and the Republic of Ireland? 
Al-Hayek S, Malone PR, Boddy JL 
Royal Berkshire Hospital, Reading, UK 
 
Introduction: 
Although prostate biopsy is the procedure of choice in diagnosing 
prostate cancer, it is not standardized. The aim of this study is to 
explore the current practice of obtaining prostate biopsies in the 
NHS units around UK and Republic of Ireland. 
Materials and Methods: 
Postal questionnaire was sent to 340 members of the British 
Association of Urological Surgeons (BAUS) working at 187 
NHS hospitals. BAUS members’ handbook 2002/2004 provided 
contact details.  This covered the 21 regions specified in the 
urology book 1998 for United Kingdom and Republic of Ireland. 
The questionnaire detailed the following information; the grade 
and speciality of the operator, biopsy indications, pre biopsy 
preparations, counselling about complications, the number of 
biopsies taken, use of antibiotics, local anaesthetic, analgesia, 
how and when the pathology results are given to patients.  
Results: 
Overall response rate was 61%. Urologists performed 65% of the 
prostate biopsies whereas 22% were undertaken by radiologists 
and 24% were shared. The majority (76%) used age based PSA 
values at which prostate biopsy deemed to be indicated, however, 
the age related values varied. The number of biopsies taken 
ranged from 2 to 24 samples. Aspirin was stopped in 34% of 
patients prior to the procedure in comparison to Clopidogrel 
which was stopped in 49%. Interestingly, large minority (41%) 
did not use any sort of analgesia before taking the biopsy. 
Although the vast majority (96%) gave patients prophylaxis 
antibiotics, numerous (43) different combinations of antibiotics 
were prescribed.  
Conclusion: 
As a gold standard method of diagnosing a very common and 
important cancer, prostate biopsy does not follow the same 
guidelines in different NHS trusts. A national study comparing 
the pick up rate and patients’ satisfaction is needed to clarify the 
requirements for a safe, comfortable and diagnosing biopsy.  
 
 
Protocol for use of Zoledronic Acid in men with Hormone 
Refractory Prostate Cancer 
Dr.David Dodds, Dr.Martin Russell 
Beatson Oncology Centre, Western Infirmary, Glasgow 
 
Skeletal related events are frequent and debilitating events in 
Hormone Refractory Prostate Cancer (HRPC).  Treatment of 
these events can account for as much as 50% of the total 
treatment costs of an individual with prostate cancer (Groot, M.T, 
et al. Eur.  Urol.2003;43:226-232) Zoledronic acid has been 
shown to reduce skeletal related events in men suffering from 
hormone independent prostate cancer (Saad et al. J. Natl Cancer 
Inst.2002;94:1458-1468, Lipton A et al. Cancer 
Invest.2002;20:45-55.).  These include pathological fractures, 
episodes of hypercalcaemia and need for palliative radiotherapy.  
There is also an improvement in pain control and quality of life.  
No other bisphosponate has been shown to do this. 
Questions remain regarding optimal timing of introduction of the 
drug and also how long treatment should be continued.  The 
question of integration of Zoledronic acid with other existing 
supportive and palliative therapies is also unclear at present.  The 
following document is an attempt to offer practical solutions to 
some of these issues utilising the available data as well as 
departmental experience gained with the drug over the last year. 
Existing recommendations/treatment algorithm are based on the 
Third International Consultation on Prostate Cancer, June 21-23: 
2002  
The Scottish Medicines Consortium summary on the proposal for 
introduction of Zoledronic Acid in hormone refractory metastatic 
prostate cancer states that there is “a reduction in skeletal related 
events compared to placebo” It was the opinion of the SMC that 
this risk reduction of 36% for the first skeletal related event and 
40% for the second event on multi-event analysis was insufficient 
to allow introduction of Zoledronic acid into standard practice. 
In the light of the SMC decision and the evidence quoted, the 
BOC has drawn up the following protocol for Zoledronic acid use 
in HRPC in an attempt to standardise treatment within the 
department and to try to target therapy to those most likely to 
benefit. 
References: 
1. Groot, M.T, et al.  Costs of Prostate Cancer Metastatic to the 
Bone in Netherlands. 
Eur.  Urol.2003;43:226-232 
2. Saad et al.  A Randomised, placebo controlled trial of 
Zoledronic acid in patients with  
hormone refractory metastatic prostate carcinoma. 
J. Natl Cancer Inst.2002;94:1458-1468 
3. Lipton A et al.  The new bisphosphonate , Zometa decreases 
skeletal complications in     
both osteolytic and osteoblastic lesions: a comparison to 
Pamidronate. Cancer invest.  
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Co-repressor complexes as targets for epigenetic therapy 
Lyndon M. Gommersall, Henry S.O. Coulter, Asad Abedin, 
Donna M. Peehl, Alan P. Doherty, Nicholas D. James and  
Moray J. Campbell, 
 
Introduction 
Prostate epithelial cells express a broad complement of nuclear 
receptors including not only the androgen receptor but others 
which have an overt role is sensing nutrient and xenobiotic 
factors. For example, normal prostate epithelial cells are acutely 
sensitive to the antiproliferative action of several micro and 
macro nutrients such as the active forms of vitamins A and D. 
Often prostate cancer cell lines and primary cultures display 
suppressed sensitivity to these factors. We hypothesized that 
epigenetic mechanisms in prostate cancer cells suppress the 
ability of anti-mitotic nuclear receptors to transactivate key 
antiproliferative target genes thereby resulting in insensitivity to 
environmental signals. To dissect these relationships we have 
focussed on the vitamin D3 receptor (VDR) and peroxisome 
proliferator activated receptors (PPAR). 
Materials and Methods 
In silico and in vitro protocols measured receptor levels, for 
example quantitative reverse transcription real time PCR (Q-RT-
PCR) to measure PPAR and VDR mRNA levels and three known 
associated co-repressors (NCoR1, NCoR2/SMRT and Alien). 
Normal prostate epithelial cells (PrEC), cancer cell lines (LNCaP, 
PC-3 and DU-145) and primary cultures of prostate cancer (n = 
12) and normal peripheral zone (n = 8) were examined. 
Receptor/co-repressor complexes were targeted with histone 
deacetylase (HDAC) inhibitors, either sodium butyrate (NaB), 
Trichostatin A (TSA) or Suberoylanilide hydroxamic acid 
(SAHA) in combination with nuclear receptor ligand. Parallel 
studies used siRNA approaches. The effects of these treatments 
were explored by proliferation and apoptosis studies, microarray 
approaches and target gene regulation by Q-RT-PCR.  
Results 
We found in silico that normal prostate epithelial cells express a 
rich compliment of at least 14 nuclear receptors, including FXR, 
LXR and ERR which provide a hitherto unsuspected local 
nutrient-sensing capacity.  Cancer cell lines and primary cancer 
cultures frequently expressed significantly elevated 
NCoR2/SMRT levels, which correlated with reduced 
antiproliferative sensitivity for example to the VDR ligand 
1,25(OH)2D3. Thus 8/12 primary tumour samples had elevated 
NCoR2/SMRT mRNA levels (mean 4.2 fold increase); generally 
NCoR1 and Alien were infrequently elevated (3/12 and 2/12 
respectively). Furthermore the antiproliferative action of a wide 
range of nuclear receptor ligands can be dramatically and 
significantly enhanced by co-treatments of ligand plus low doses 
of either NaB, TSA of SAHA. Interestingly cell fates differed. 
Thus treatments of 1 25(OH)2D3  plus HDACi induced apoptosis, 
whereas PPARγ ligands plus HDACi resulted in type II 
(autophagic) non-apoptotic programmed cell death.  cDNA 
microarray and gene expression studies confirmed the unique and 
significant up regulation of a number of antiproliferative target 
genes including MAPK-APK2 and GADD45 alpha. Supportively 
primary cancer cultures with elevated NCoR2/SMRT 
demonstrated suppressed GADD45 alpha induction compared to 
matched normal controls. Subsequently we knocked-down 
NCoR2/SMRT levels in PC-3 cells using siRNA resulting in a 
95% reduction in the basal levels of SMRT mRNA after 72 hr, 
and found that GADD45 alpha induction by 1,25(OH)2D3  alone 
became very significantly enhanced 
 
Conclusions 
These data demonstrate that the nuclear receptor co-repressor 
NCoR2/SMRT is commonly elevated in prostate cancer cells and 
drives transcriptional and therefore cellular insensitivity to a 
broad portfolio of nuclear receptor ligands. Individual molecular 
diagnostic profiling of early stage cancers will highlight 
individuals who would respond to targeting the co-repressor 
complex either through pharmacological or nutritional 
intervention.  
 
Novel anticancer properties of pomegranate extracts; 
suppression of proliferation, invasion and xenograft growth 
of human prostate cancer cells 
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Divisions of Medical Sciences [LMG, MJC], University of 
Birmingham Medical School, Edgbaston, Birmingham. B15 2TH, 
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Marburg, GERMANY [MA], Division of Science, College of 
Liberal Arts, Florida Atlantic University, Davie, Florida, USA 




We have investigated the effects of several Pomegranate fruit 
(Punica granatum) extracts on the proliferation of normal, benign 
hypertrophic, and malignant prostate cells.  
Methods  
Cell proliferation and cell cycle analyses combined with staining 
of apoptotic cells were used to determine the effects of cold-
pressed seed oil (Oil), fermented juice polyphenol fractions (W) 
and aqueous pericarp extract (P) on prostate cells. To evaluate 
changes in the gene expression profile following extract 
stimulation, we performed real-time RT-PCR studies. In vitro cell 
invasion assays and xenograft experiments were performed to test 
the influence of pomegranate extracts on cell invasion and 
metastasis. 
Results 
Oil, W and P all acutely inhibited in vitro proliferation of LNCaP, 
PC-3 and DU 145 cancer cell lines. The dose of P required to 
inhibit cell proliferation of the prostate cancer cell line LNCaP by 
50% (ED50) was 70 micro g/ml, whereas normal prostate 
epithelial cells (hPrEC) were significantly less affected (ED50 250 
g/ml).  
These effects were mediated by changes in both cell cycle 
distribution and induction of apoptosis. For example, the 
androgen independent cells DU 145 cells showed significant 
increase from 11% to 22% in G2/M cells (p<0.05) by treatment 
with Oil (35 micro g/ml) with a modest induction of apoptosis. In 
other cell line and treatment combinations the apoptotic response 
predominated, for example PC-3 cells treated with P. These 
cellular effects coincided with rapid changes in mRNA levels of 
gene targets. Thus, 4 hr treatment of DU 145 cells with Oil (35 
micro g/ml) resulted in significant 2.3 fold upregulation of the 
cyclin dependent kinase inhibitor p21(waf1/cip1) (p<0.01) and 0.6 
fold downregulation of c-myc (p<0.05).  In parallel, all agents 
potently suppressed PC-3 invasion through Matrigel, and 
furthermore P and supercritical CO2 extracted pomegranate seed 
oil (S) demonstrated potent inhibition of PC-3 xenograft growth 
in athymic mice.  
Conclusions 
Overall this study demonstrates significant in vitro and in vivo 
antitumor activity of pomegranate-derived materials against 
human prostate cancer. 
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The potential use of Kerr gated Raman spectroscopy to 
diagnose prostate cancer. 
Hart Prieto M. C, Crow P, Matousek P*, Parker A. W*,  
Wright M, Ritchie A. W, Stone N. 
Gloucestershire Royal Hospital 
*Central Laser Facility, Rutherford Appleton Laboratory 
 
Introduction: 
Raman spectroscopy is an optical technique that is able to 
interrogate biological tissues. In doing so it gives us an 
understanding of the changes in the molecular structure that is 
associated with disease development. The Kerr gating Technique 
uses a picosecond pulsed laser as well as fast temporal gating of 
inelastically (Raman) scattered light. The scattered light is 
collected at various time delays following the laser pulse. In 
utilising these techniques it was felt that Raman spectroscopy 
could be used to not only distinguish between pathologies within 
the prostate gland, but also to depth profile the prostate gland 
thereby increasing their potential use in vivo. 
Materials and Methods: 
The samples used for this study were taken following fully 
informed consent and ethical approval. Prostate samples were 
obtained by taking a chip at TURP. The samples were then snap 
frozen in liquid nitrogen and transferred to an -80°C freezer for 
storage. The samples were passively warmed and then scanned 
on an Optimised Raman System (Renishaw System 1000), to 
obtain in vitro Raman spectra. The prostate sample was placed 
onto a cell containing urea and then scanned. The Kerr gating 
system is based on the high throughput 4 picosecond optical Kerr 
shutter that was described in previous publications by Matousek 
et al (1, 2), and was used for depth profiling. 
Results: 
The spectra obtained as we go through the prostate gland tissue 
and on to the urea cell, clearly show the change in the spectra. 
The first 3 spectra are clearly tissue spectra with peaks at 
1445cm-1 and 1650cm-1, which are consistent with protein 
peaks. The 4th spectrum has lost a lot of the signal and then in the 
following spectra the urea peak is clearly seen at 1003cm-1, and 
there is a loss of the protein peaks that are consistent with tissue. 
Conclusion: 
We have shown for the first time that we are able to obtain 
spectra from different depths through the prostate gland. This has 
major implications in the future of Raman spectroscopy as a tool 
for diagnosis. Up until now we have been able to distinguish 
between different pathologies within the prostate gland by 
sampling the tissue in vitro. This involves only looking at the 
surface of the sample. The prostate gland is usually biopsied via 
the rectum. This is a painful procedure and can give false 
negatives. With the help of Raman spectroscopy and Kerr gating 
we potentially would be able to pick up the spectral differences 
from a small focus of adenocarcinoma of the prostate gland in an 
otherwise benign gland. 
References: 
1. Matousek et al. Appl.Spectrosc 1999; 53: 1485.  
2. Matousek et al. J. Raman Spectrosc 2001; 32: 983. 
 
 
Prostate brachytherapy using the Bard Proseed technique: 
The Northampton experience. 
RB Kunkler*, CRW Bell*, P Goldie, S Duggleby, T Hall*,  
C Elwell#. 
Departments of Urology*, Oncology# and Medical Physics 
Northampton General Hospital NHS Trust 
 
Introduction 
Prostate brachytherapy is an increasingly used option for the 
treatment of clinically localised prostate cancer. Advances in 
software design have led to the development of intraoperative 
dosimetry planning allowing radioactive seed implantation to be 
performed without the need for a separate volume study and 
preoperative planning. We report our initial clinical results and 
dosimetry data using the Bard Proseed technique for I125 seed 
implantation in a consecutive series of 55 patients.  
Method 
From May 2002 patients with clinically localised prostate cancer 
opting for brachytherapy were prospectively assessed 
preoperatively, with International Prostate Symptom Score 
(IPSS), sexual dysfunction score (SDS) and uroflowmetry. 
Patients were started on tamsulosin before implantation. 
Brachytherapy was performed under general anaesthesia 
according to the Bard Proseed technique. The urethral catheter 
was removed on completion of the procedure. The patient was 
discharged the following day when satisfactory voiding was 
achieved. Patients were followed up with PSA, IPSS, SDS and 
flow rate tests 3 monthly intervals for the first year, and 
subsequently at 6 monthly intervals thereafter. A CT scan of the 
prostate was performed 6 weeks after the implant in order to 
calculate post-implant dosimetry. 
Results 
55 patients (clinical stage T1c to T2c) with a mean age of 63 
years (range 52 – 77) underwent treatment. The mean prostate 
volume was 38cc (range 14 – 88cc) The mean PSA fell from a 
pre-implant level of 7.8ug/L to 1.8, 1.3, 1.2, 0.9 and 0.8ug/L at 3, 
6, 9, 12 and 18 months respectively. The mean pre-implant IPSS 
of 6.9 rose to 15 three months after implantation and 
subsequently subsided to 11.9, 10.6, 6 and 5.8 at 6, 9, 12 and 18 
months respectively. The mean pre-implant SDS of 24 changed 
to 15.8, 22, 24.1, 24.8 and 24.6 at 3, 6, 9, 12 and 18 months 
respectively.   Three patients required a catheter for longer than 2 
weeks and 2 of these have subsequently resumed satisfactory 
voiding. No patient has yet required a TURP. Only one patient 
has developed significant (Grade 2) rectal toxicity.  
All patients achieved the prescribed intraoperative (160Gy) and 
postoperative (140Gy) minimum dose to 90% of the prostate 
(D90). Mean doses achieved were 192 and 175Gy respectively. 
No patient exceeded the maximum intraoperative  dose to 30% of 
the urethral volume (Urethral D30). The mean postoperative 
Urethral D30 was 229Gy, with 16 patients exceeding the 
proscribed limit. However has not been reflected in increased 
urinary symptoms in this group. 
Conclusion 
Prostate brachytherapy using the Bard Proseed technique has 
achieved excellent dosimetric results in all patients with a 
predictable fall in PSA to a nadir after 12 months.  Urinary 
symptoms are universally increased following the implantation, 
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Introduction: 
There is a requirement for novel chemotherapeutic agents in the 
prevention or treatment of bone metastases in prostate cancer. 
AZD3409 is a novel oral ras protein prenyl transferase inhibiting 
both the Farnesyl Transferase pathway and the Geranylgeranyl 
escape pathway, with significant theoretical advantages over 
existing prenylation inhibitors.  
Materials and Methods:  
The anti-proliferative effect of escalating doses of AZD3409 on 
malignant PC-3 and LNCaP and non-malignant PNT2-C2 cell 
lines were tested in culture. Proliferation of isolated primary 
prostate epithelial cells from patients undergoing TURP was also 
quantified. PC-3 and PNT2-C2 cell colony formation was 
measured in co-culture using long-term human bone marrow 
stroma in the presence of escalating doses of AZD3409.  The 
effect of AZD3049 on prostatic cellular invasion through 
matrigel (synthetic basement membrane) and through a cultured 
endothelial monolayer was also determined in invasion chambers 
using cytokeratin labeled quantitation of migrating cells. A mix 
assay system was employed to determine the effect of AZD3409 
on haemopoietic progenitor colony formation.  
Results:  
AZD3409 displayed marked anti-proliferative properties on the 
PNT2-C2, PC-3 and LNCaP prostate epithelial cell lines. There 
was an IC50 of 9.81nM, 73.85nM and 22.06nM respectively after 
3 days of exposure to AZD3409. There was also significant 
inhibition of primary BPH epithelial cells after 3 days of 
exposure, with an IC50 of 278.7nM. AZD3409 inhibited invasion 
through bone marrow endothelium towards bone marrow stroma, 
with an IC50 of 31.0nM, levels known to be attainable in vivo.  
AZD3409 also inhibited PC-3 colony formation in primary 
human bone marrow stroma. Co-cultures grown in the presence 
of escalating drug concentrations resulted in reduced numbers of 
colonies (IC50 of 160.2nM) and reduced epithelial colony size 
(IC50 of 59.9nM). AZD3409 had no significant effect on bone 
marrow progenitor colony formation and no statistical 
significance between counts of any of the drug doses or the 
controls was demonstrated (p=0.227). 
Conclusions:  
AZD3409 is a potent inhibitor of malignant and non-malignant 
prostate epithelial cell proliferation. AZD3409 is a potential anti 
metastatic agent inhibiting prostate epithelial cell invasion 
towards bone marrow stroma and inhibiting colony formation 




The role of Serotonin (5HT) and 5HT antagonists in prostate 
cancer 
E Siddiqui, M Shabbir, C Thompson, D P Mikhailidis, F Mumtaz 
Department of Surgery/Chemical Pathology, Royal Free Hospital 
and University College Medical School, University College 
London, Pond Street, Hampstead, London. NW3 2QG.  
 
Introduction  
The ability of prostate cancer to survive androgen withdrawal 
therapy has led to a search for alternative pathways for control of 
tumour growth.  Data indicates an increase in neuroendocrine 
cells in malignant prostate tissue. These cells release growth 
factors including neuropeptides and biogenic amines which are 
correlated to tumour progression, androgen independence and 
poor prognosis. 
Serotonin (5HT) a monoamine neurotransmitter mediates a wide 
range of physiological activities by binding to receptor subtypes. 
We evaluated the effect of Serotonin (5HT) and 5HT receptor 
subtype antagonists on the growth of prostate cancer.  
Materials and Methods 
PC3 cells (androgen independent human prostate cancer) were 
obtained from the American Type Culture Collection. The cells 
were plated in serum supplemented growth medium at 5000 cells 
per well in 96 well plates. Drugs were added after 24 hours. The 
effect of Serotonin (5HT) and 5HT receptor antagonists on PC3 
cell line was studied via colorimetric assay using crystal violet 
and was read using a spectrophotometric plate reader. Readings 
were done at 72 hours after addition of drugs. 
Results 
The 5HT receptor subtype antagonists used were 5HT1A, 
5HT1B, 5HT1D, 5HT2, 5HT3, 5HT4. There was no 5HT1C 
receptor antagonist available.  5HT1B antagonist has a dose 
dependant growth inhibitory effect on PC3 cells inhibiting 78% 
(n=12, P< 0.05) cell growth at a concentration of 10−4M at 72 
hours. 5HT1A antagonist has a 20% (n=12, P<0.05) growth 
inhibitory effect on PC3 cells at the same concentration at 72 
hours. The remaining 5HT receptor subtype antagonists had no 
effects on cell growth. Serotonin (5HT) caused a dose dependant 
cell proliferation leading to a 15% (n=12, P<0.05) increase in 
cells at a concentration of 10−8M as compared to control at 72 
hours. 
Conclusion 
Serotonin (5HT) leads to proliferation of prostate cancer cells 
whereas the 5HT1B receptor antagonist and to a lesser extent 
5HT1A receptor antagonist have a growth inhibitory effect. 
Therefore, our results of growth inhibition of human prostate 
cancer cells by serotonin antagonists in vitro have suggested that 
5HT antagonists, in particular 5HT1B receptor antagonist should 
be studied in detail as an anti-neoplastic agent. 
 
 
Risk of cancer on follow-up biopsy following a diagnosis of 
prostatic intra-epithelial neoplasia on core biopsy. 
Cane P, Kirby R, Corbishley C 
St George’s Hospital London 
 
Introduction:  
Prostatic intra-epithelial neoplasia (PIN) is associated with 
synchronous invasive carcinoma. The aim of our study was to 
quantify the rate of invasive carcinoma on follow-up core biopsy 
after an initial diagnosis of PIN. We also investigated factors that 
could predict the presence of invasive cancer i.e. Number and 
bilaterality of involved cores at initial diagnosis and PSA level. 
Materials and Methods:  
We identified a total of 57 patents who had PIN diagnosed by 
octant core biopsy between 2000 and 2003 in our department and 
had undergone follow-up biopsies.  
Results:  
28% (16 of 57) cases showed invasive cancer on follow-up 
biopsy. The rate rose to 40% (8 of 20) if more than one core was 
involved at initial biopsy and to 50% (8 of 16) if cores from both 
sides of the prostate were positive at initial biopsy. No significant 
predictive value was found for PSA and PSA Density values at 
time of initial biopsy. In 46% (26 of 57) of cases, the repeat 
biopsy showed PIN but no invasive cancer. Eleven of these cases 
went on to have a third set of biopsies, 2 of these showed 
invasive cancer and 4 contained further PIN. 
Conclusion:  
We confirm the presence of PIN in core biopsies carries a 
significant risk of there being concurrent invasive tumour, 
particularly if more than one core and cores from both sides of 
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the gland contain PIN. PSA values were not useful in predicting 
the presence of cancer. 
 
 
The effect of ethnicity on PSA failure following radical 
retropubic  prostatectomy. 
C.J. Luscombe, J.G. Young, P.G. Ryan 
City Hospital, Birmingham 
 
Introduction:  
There are no reported UK data concerning the effect of ethnicity 
on PSA failure following radical therapy for prostate cancer, and 
data from other countries are conflicting. 
Materials and Methods:  
The study group comprised 98 Caucasians and 28 Afro-
Caribbeans who had a radical retropubic prostatectomy (RRP) 
performed by one surgeon between 1997 and 2003. Data were 
retrospectively collected. The statistical significance of variables 
on the time to PSA failure was calculated using Cox's regression. 
PSA failure was defined as a post procedure PSA>0.1ng/ml. 
Results:  
Pre-operative PSA was higher in the Afro-Caribbean group 
(p=0.013); median=15ng/ml, compared with 9ng/ml, however 
there were no differences in Gleason score>6, positive margin 
rates, seminal vesicle involvement (SVI), extra-capsular 
extension (ECE), perineural invasion or age. 20% of patients 
developed PSA failure during follow-up with an excess in the 
Afro-Caribbean group (Fisher’s exact test, p=0.03). However, the 
mean follow up was longer for Afro-Caribbeans (834 days 
compared to 694). To control for this, time to PSA progression 
was studied. Only 3 of the variables listed above were significant 
independent predictors of time to PSA failure; Gleason score>6 
(p=0.007, Hazards Ratio (HR)=3.2, 95% Confidence Interval 
(95%CI)=1.4-7.5), ethnicity (p=0.012, HR=2.9, 95%CI=1.3-6.6) 
and ECE (p=0.008, HR=3.1, 95%CI=1.3-7.1). In a multivariate 
analysis of all the variables, ethnicity was again a significant 
predictor (p=0.012, HR=4.5, 95%CI=1.4-14.5), as was positive 
margin rate (p=0.042, HR=2.6, 95%CI=1.0-6.4). 
Conclusion:  
These data confirm well-established predictors of PSA failure 
following RRP. Furthermore they demonstrate a significant 
association between ethnicity and time to PSA failure. 
 
 
A comparison of the multidisciplinary team approach to men 
with clinically localised prostate cancer in two West London 
hospitals, and the difference in their choice of radical 
treatment 
E Rowe *, O Karim+, A Pope*, M Laniado+, H Motiwala+,  
J Maher*, V Mishra+, S Niewiorwski* 
Wexham Park Hospital +, and Hillingdon Hospital * 
 
Introduction 
The aim of this study was to compare the Multidisciplinary Team 
approach (MDT), and treatment choices, of men with clinically 
localised prostate cancer in two West London Hospitals.  
Materials and Methods 
Men with clinically localised prostate cancer deemed suitable for 
radical treatment by the MDT panel where included in the study. 
A telephone interview was conducted in which men were asked 
the reasons for their treatment choice, and their attitudes towards 




Thirty two men (mean age 63.3 years, mean PSA 8.2ng/ml) from 
hospital A were compared with 29 men form hospital B (mean 
age 62.9 years, mean PSA 7.4ng/ml). Seventy five percent of 
men underwent surgery at hospital A, compared to 52% at 
hospital B. All men from hospital A saw both an oncologist and a 
surgeon compared to 79% at hospital B. Twenty five percent of 
men at hospital A saw a cancer nurse specialist compared to 76% 
at hospital B. Ninety four percent of men at both institutions liked 
the MDT approach. 
Conclusion 
In this cohort of identical groups of men with localised prostate 
cancer the majority of men liked the MDT approach, but the 
process differs in different institutions, as does the outcome in 




The BAUS Cancer Registry – An inaccurate reflection of the 
proportion of histologically-confirmed prostate cancer in 
clinical practice? 
B Patel1, R Persad2 
(Departments of Urology, Bristol Urological Institute1, and 
Bristol Royal Infirmary2) 
 
Introduction 
Histological confirmation of prostate cancer should be the “gold 
standard”. However, in clinical practice, patients are sometimes 
diagnosed and treated in the absence of histological confirmation. 
Such a “clinical diagnosis” on the basis of an elevated PSA, high 
suspicion on DRE or other positive imaging may be a reasonable 
approach. The BAUS Cancer Registry Database (2002) states that 
93.2% of the recorded cases of prostate cancer have histological 
confirmation. Individual hospitals record the diagnosis of prostate 
cancer on the Patient administration system (PAS) or Hospital 
Episode Statistics (HES). 
This study investigates the rates of histological confirmation of 
prostate cancer in clinical practice, makes comparisons with the 
BAUS Cancer Registry and evaluates the reliability of a 
diagnosis of prostate cancer on the hospital PAS database. 
Materials and methods 
A retrospective study of 54 consecutive, newly diagnosed cases 
of prostate cancer recorded on the PAS database at a tertiary 
referral centre. The hospital histology database and PAS were 
searched in order to identify newly diagnosed and recorded cases 
of prostate cancer respectively. The results of both were then 
cross-referenced. The case notes of the identified patients were 
then examined to determine the basis for the diagnosis, and the 
relevant investigations. 
Results 
The PAS list identified 54 new cases of prostate cancer, 37 of 
which featured on the histology database. On case note review, 2 
of the patients identified as having prostate cancer on PAS did 
not, in fact, have the disease and had been wrongly listed due to 
coding inaccuracies. The histology database identified 39 cases. 1 
case had their histology omitted from the histology database. 2 
patients with histological confirmation did not feature on the PAS 
list. 14 patients had a clinical or non-histological diagnosis of 
prostate cancer. Our rate for histological confirmation was 
74.1%, with 25.9% of patients having no histological 
confirmation. The reason for the absence of confirmatory 
histology in these cases was usually high clinical suspicion in an 
elderly and frail patient, who, consequently, was not subjected to 
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a positive predictive value of the same. The sensitivity of the 
histology database was 72.2%. 
Conclusion 
Our rate for histological confirmation of prostate cancer (74.1%) 
is well below the figure quoted by the BAUS Registry, and 
reflects actual clinical practice where we are not registering many 
such cases. This may be partly explained by the fact that many 
consultants who submit to the BAUS Registry rely on their 
histology departments to prompt registration of new patients. 
Patients with a non-histological diagnosis may therefore be 
omitted from the registry as would patients primarily under the 
care of a non-urologist. We need to improve the registration of 
non-histologically confirmed prostate cancer cases by the BAUS 
Registry, and suggest that a combination of the hospital PAS or 
HES databases and the histology database be used in order to 
identify new cases and prompt registration. 
 
 
Ultrasonic Shears in Open Radical Retropubic Prostatectomy 
McCabe JE, Javle PM 
Michael Heal Department of Urology, Leighton Hospital, Crewe 
 
Introduction 
Ultrasonic Shears (USS) are a cutting and coagulating surgical 
instrument. The device operates at a frequency of 55.5kHz 
through the conversion of electrical to acoustic energy. The 
advantages of the device are the reduction in lateral thermal 
tissue damage, combined cutting and coagulation in the same 
device and greater precision near vital structures. The instrument 
is used primarily in laparoscopy. We tested its use, by direct 
comparison with traditional methods of dissection and 
haemostasis, in open radical retropubic prostatectomy (RPP). 
Materials and methods 
Patients undergoing RPP were assigned to two groups and either 
underwent the procedure with the aid of the USS (Autosonix, 
Tyco Healthcare) or by traditional methods of haemostasis 
(control). The groups were analysed according to blood loss, 
operative time, post-operative complications and hospital stay. 
Blood loss was calculated by peri-operative drain loss and swab 
weight. Total transfusion was also recorded. 
Results 
Forty patients were analysed, of whom 22 underwent RRP in the 
control group (mean age 63, mean prostate weight 43.5g) and 18 
in the USS group (mean age 59, mean prostate weight 76.8g).  
There was a significant decrease in mean peri-operative blood 
loss with the USS group from 1392.5ml (control) to 587.5ml 
(p<0.001). This is reflected in a reduction of mean transfusion 
from 0.8 to 0.0 units. Operative time was improved with 
Autosonix from a mean of 195.3 to 175.6 minutes (p=0.02). 
Hospital stay also showed a reduction from 5.3 to 4 days 
(p<0.001). 
Conclusion 
This preliminary study strongly suggests that the use of the 
ultrasonic shears in RRP reduces blood loss, operative time and 









Measuring tissue mechanical characteristics to assess 
malignant prostatic disease 
S. Phipps1, T.H.J. Yang2, F.K. Habib1, R.L. Reuben2,  
S.A. McNeill3 
1Prostate Research Group, University of Edinburgh, Western 
General Hospital, Edinburgh, UK.  
2School of Engineering and Physical Sciences (Mechanical 
Engineering), Heriot–Watt University, Edinburgh, UK. 




The mechanical behaviour of biological tissue shows a 
combination of viscous and elastic elements. Tissue mechanical 
properties can be derived by measuring the alterations to an 
energy wave passed through the sample. Using a novel test 
method, we sought to establish whether differences exist between 
benign and malignant prostatic tissue specimens assessed in vitro, 
and whether these were related to differences in tissue 
morphology. 
Materials and Methods 
Fresh tissue specimens were collected from patients undergoing 
TURP, 11 for benign (BPH) and 11 for malignant (PCa) prostatic 
enlargement. Using a specially designed test rig, individual 
TURP chippings underwent immediate mechanical testing, by 
applying a dynamic compressive strain to the samples. The 
amplitude ratio (|E*|) and phase difference (tan δ) between the 
energy waves entering and arising from the tissue, measures of 
tissue elastic and viscous components respectively, were derived.  
Individual sections from the processed specimens underwent 
immunohistochemical staining and computerised image analysis 
was used to measure the morphological characteristics of each 
TURP chipping. Mean values for each prostate were then 
calculated. Unpaired t-test assuming equal variances was used to 
compare the mechanical and morphological characteristics of 
BPH and PCa prostates and linear regression analysis was used to 
assess correlations between morphological and mechanical 
measurements. 
Results 
There were significant differences between the morphology of 
the BPH and PCa prostates. There was a significantly greater 
epithelial tissue (ET) content within the PCa prostates (p=0.01), 
which was composed of glandular acini whose mean area was 
significantly smaller than within the BPH prostates (p=0.0008).  
Tan δ was significantly smaller within the PCa prostates (p=001). 
There was no difference between the BPH and PCa prostates with 
respect to |E*|. Within the PCa prostates, there was a strong 
negative correlation between the ET content and tan δ (R2=0.58, 
p=0.001). 
Conclusions 
This study shows that measurable differences exist between the 
mechanical characteristics of benign and malignant prostates. 
These differences reflected the composition of the tissues, and 
there were significant correlations between prostatic tissue 
morphology and its mechanical characteristics. The ability to 
quantify prostatic tissue mechanical characteristics in vivo may 
allow the detection of malignancy, and by reflecting the volume 
and grade of the malignant tissue present, may aid in the staging 
of PCa. We therefore believe that this approach may be of 
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Laparoscopic vs. open radical retropubic prostatectomy —
peri-operative cost comparison and experimental predictive 
model for costing at a tertiary U.K. referral centre 
Sashi Kommu, Suril Patel, Mark P Wright, Raj A Persad 
Bristol Urological Institute, Bristol, U.K. 
 
Introduction  
Laparoscopic radical prostatectomy (LRP) is becoming a gold 
standard treatment for localised prostate cancer in many units. 
Very few studies have looked at the economic impact of LRP 
despite the need for validation of this relatively new technique 
from a health economics point of view. The aim of our study was 
to perform a detailed comparison of the perioperative costs of 
patients undergoing laparoscopic radical prostatectomy and open 
radical retropubic prostatectomy (ORP) and to develop a 
predictive model for estimation of perioperative cost applicable 
in a U.K. setting. 
Materials and Methods  
A retrospective cost review was done of a cohort of randomly 
chosen cases from a database pool of radical prostatectomies 
performed during a 36-month period. 15 cases were selected from 
the LRP group and 15 from the ORP group. The hospital costs 
were evaluated for each patient using the categories of 
anaesthetic consumables, surgical consumables, post operative 
analgesia, antibiotics, blood units transfused and post operative 
days on ward. We omitted factors such as personnel fees and 
operating room time as these are not standardised and are subject 
to wide variability often only partially reflective of the actual 
procedure. We also developed a predictive model for estimation 
of cost and tested its applicability in predicting costs at two 
independent hospitals using their database of 2 LRP and 2 ORP 
cases. 
Results  
The median perioperative costs for surgical consumables were 
LRP=402.27 GBP vs. ORP=184.87 GBP.  
The median perioperative anaesthetic consumables cost was 
LRP=225.15 GBP vs. ORP=168.84 GBP. Postoperative analgesia 
cost was LRP=10.13 GBP vs. ORP=14.43 GBP. There was no 
difference in antibiotic costs in the two groups (9 GBP). The cost 
of transfusing one unit of blood in the U.K. is 122.28 GBP. The 
transfusion rate for ORP was (2/15=13.3% i.e. average of 16.26 
GBP per patient) vs. (1/15=6.7% i.e. average of 8.13 GBP) in the 
LRP group. The days of stay post op were LRP =2.7 vs. ORP 3.8. 
The median perioperative costs of patients undergoing LRP 
(662.81 GBP) were higher than ORP (393.40; P = 0.001). Our 
prediction model was able to estimate that on average a LRP will 
cost 1.7 times more than ORP using specific fixed variables. 
[GBP-Great Britain Pound] 
Conclusion  
Our study shows that the standard costs of LRP are greater than 
ORP by a factor of 1.7 if total hospital admission time is 
excluded. If hospital time spent is included the patient who 
undergoes ORP stays on average (3.8/2.7) 1.4 times longer than 
the LRP patient. The offset in costing as a result of the longer 
admission time in ORP depends on individual cost of a room per 
day. Our findings are reflective of some United States studies, 
which found that the cost of LRP is greater than ORP by a factor 
of approximately 1.5. The differences between open and 
laparoscopic radical prostatectomy remain to be fully defined in 
terms of long term oncological and qality of life outcomes but we 
feel that we have made a contribution in defining the procedure 
that places greater financial stress on NHS resources in the 
current health economic climate. Large-scale studies are needed 
to further validate our preliminary findings. Our cost prediction 
model may aid in defining some of the cost parameters and act as 
a template to build upon for further improvements in costing. 
 
 
Periprostatic infiltration of local anaesthetic during  
transrectal ultrasound-guided biopsy of the prostate in an 
office based setting-the analgesic efficacy in a typical  
U.K. District General Hospital 
Sashi Kommu, Amit Dhulkotia, Ravee S Surange, Vincent 
Gonzales and  Neeraj K Sharma 
The Royal Oldham Hospital, The Acute Pennine Hospitals NHS 
Trust. Oldham.  
 
Introduction  
Transrectal ultrasound (TRUS) guided needle biopsy of the 
prostate is the standard procedure to diagnose prostate cancer. 
With the current exponential increase in the number of men being 
biopsied to rule out prostate cancer, pain control and patient 
comfort are of major concern. Most published studies regarding 
use of local anaesthetic (LA) during TRUS biopsy were done in 
specialist centres in the past. The aim of this study was to test the 
analgesic efficacy of periprostatic infiltration of local anaesthetic 
during TRUS biopsy of the prostate and to look at complication 
rates in a typical U.K. district general hospital in an office based 
setting. 
Materials and Methods  
This was a prospective clinical trial in which a total of 308 
patients were studied. Patients were sequentially allotted into two 
groups. In one group all men received a total of 15 mL of 1% 
lidocaine in the lateral and apical periprostatic regions, 5 mL in 
each point, approximately 10 minutes before the prostate biopsy. 
The other group received no analgesic. Pain after each biopsy (a 
total of 8-12 biopsies) was assessed using a 10-point linear visual 
analog pain scale to record visual analogue pain scores (VAS). 
We also looked at immediate and late complications associated 
with the procedure by establishing a nurse specialist lead follow 
up network. 
Results  
Patients who received LA had significantly lower pain scores 
compared to  those not given analgesic. The relative risk of 
patients not given LA feeling pain was 2.9 ( 95 % confidence 
interval  2.3-3.6 ; P<0.00001) compared to those not receiving 
analgesic. There was no significant difference in complication 
rates between the two groups. 
Conclusion  
Periprostatic infiltration of LA significantly decreases pain in 
TRUS guided biopsy of the prostate with no additional risk of 
complications. We advocate the routine use of this procedure in 
all patients to improve patient comfort and tolerance. This study 
also shows that the procedure can be done safely and effectively 
in a district general hospital office based setting. 
 
 
PSA test, how much non urologists know? 
Mr Bashar Zelhof, Mr AJ Browning,  Mr CS Biyani 




The measurement of prostate specific antigen has contributed to 
the startling increase in the number of cases of prostate cancer 
diagnosed in the late 1980s. It was soon recognised that although 
PSA was sensitive, it lacked specificity. Concerns have being 
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from widespread PSA testing. Therefore various guidelines (1) 
have been established regarding PSA test. 
Between 1st of January 2003 and 30th of November 2003, 8350 
PSA test were requested in the pathology department of Mid-
Yorkshire NHS Trust. We noticed that 544 tests were requested 
on patients older than 85 years and 123 tests on patients less than 
35 years of age. 
We investigated the level of awareness hospital-doctors and GPs 
regarding the PSA guidelines. 
Aim:  
To improve the quality of PSA requests and reduce the overall 
costs. 
Methods 
PSA questionnaires were sent by post to most GPs in Wakefield 
region, and were handed personally to most hospital-doctors in 
the relevant specialities (General Medicine, Care of Elderly, 
General Surgery and Orthopaedics),  by attending departmental 
meetings. 
The questionnaire was designed to ask clinician on PSA 
indications, normal levels, false positive, digital rectal 
examination in conjunction with PSA, awareness of guidelines 
and discussion with patients. 
We received 141 replies (52/70 GPs and 89/89 hospital doctors). 
Results: 
Most doctors know about the definition of PSA and its role in 
prostate cancer, however, factors that influence PSA and cause 
false positive results were not appreciated by majority of the 
respondents. 68% of the respondents were not aware of rise in 
PSA following instrumentation. 
Only 48% of hospital doctor perform DRE with PSA request as 
compared to 69% of GPs. 
60% of overall doctors discuss the test with their patients (92% 
GPs Vs 41% of hospital doctors). 
Knowledge of PSA guidelines among hospital doctors was low 
(10%), in contrast 61% of GPs were aware of the guidelines. 
Conclusion: 
In the light of our results we feel that continuing medical 
education on PSA is very important to minimise patient’s anxiety 
and to make it more cost effective. 
References 
1) British Association of Urological Surgeons and the 
Royal College of Radiologists’ Clinical Oncology Information 
Network. Guidelines on the management of prostate cancer, 
section 1.2 and 1.3. 
 
 
Molecular biopsy for Prostate Cancer using Carbonic 
Anhydrase XII Quantitative RT-PCR  
C. P. Pipinikas1, S. B. Nair1, 2, R. S. Kirby2, N. D. Carter1 and  
C. D. Fenske1  
2St George’s Hospital and 1Medical School, London SW17. 
 
Introduction 
The sensitive molecular technique, reverse transcriptase-
polymerase chain reaction (RT-PCR), has been shown to detect 
prostate cells in peripheral circulation.  Potential markers for CaP 
have been assessed for their accuracy in diagnosis. The hypoxia-
inducible factor-1 (HIF-1) transcriptional complex is thought to 
be an important mediator of gene expression in tumours (Ivanov 
et al., PNAS 1998; 95:12596-12601) The tumour–associated 
isozyme, carbonic anhydrase XII (CAXII), is known to be tightly 
regulated by this complex.  The involvement of CAXII in the 
acidification of the extracellular milieu (Ivanov et al., PNAS 
1998; 95:12596-12601) may contribute to the formation of a 
microenvironment, conducive to tumour growth and spread.  
Using RT-PCR and quantitative RT-PCR (qRT-PCR), CAXII was 
analysed as a potentially accurate marker in the diagnosis and 
monitoring of prostate cancer development/progression. 
Methods 
Total RNA was extracted in quadruplet from blood taken from 
112 patients. CAXII gene expression was analysed by RT-PCR 
and qRT-PCR using the LightCycler™ (Roche). 
Results 
RT-PCR results showed CAXII expression in patients diagnosed 
with benign prostatic hyperplasia (BPH, 5/7), localised CaP 
(LocCaP, 66/70) and metastatic CaP (MetCaP, 31/35). However, 
obvious differences in product band intensities were further 
investigated using qRT-PCR. Using relative qRT-PCR, mean 
CAXII expression was calculated to be 118.5 (BPH -10 patients), 
703.9 (LocCaP-8 patients) and 40.1 (MetCaP-18 patients). CAXII 
expression in the LocCaP group was 6-fold higher than that of the 
BPH group and 18-fold higher than that of the MetCaP group. No 
correlation between CAXII expression and PSA/Gleason scores 
was found.  No CAXII expression was demonstrated in 
female/male control patients. 
Discussion 
Our results demonstrate upregulation of CAXII expression in the 
LocCaP group and down regulation in the MetCaP patient group. 
The majority of MetCaP patients were hormone refractory.  As 
CAXII is hypoxia-induced (via HIF-1), this would indicate that 
hypoxia is a mechanism involved in CaP development.  However, 
down regulation of CAXII in MetCaP patients, indicates a 
possible alternative pathway that overrides the hypoxia-induced 
mechanism in hormone refractory end-stage CaP.  CAIX, another 
hypoxia-induced carbonic anhydrase isozyme has been shown to 
demonstrate a similar expression pattern, being upregulated in 
well-differentiated gastric tumours, and down regulated in poorly 
differentiated tumours (Leppilampi et al. Abstract 6th Int. Conf. 
Carbonic Anhydrases June 2003 P14). qRT-PCR is an extremely 
sensitive, accurate technique for measuring expression of 
candidate CaP markers. CAXII is a potentially excellent 
molecular marker in routine clinical diagnosis and prognosis of 
CaP.  Furthermore, CAXII is a potential target for therapy as it 




Summer Audit of TRUS Guided Prostate Biopsies 
A MacLeod, J McKnight, C Hagan 
Belfast City Hospital 
 
We audited our prostate biopsy clinic for a period of 4 weeks 
starting from the 17 May 2004.  The aims of this audit were to 
delineate the population demographics, referral patterns and 
waiting times for the clinic.  The positive biopsy rate, 
complication rate and patient satisfaction were also worked out. 
Method 
All of the patients attending the clinic during the auditing period 
were asked to participate while consent was being obtained.  All 
agreed to inclusion.  The biopsies were taken as normal, using the 
same ultrasound probe for all biopsies, by 5 different operators  
After informed consent was obtained, the patient was given 
120mg gentamycin.  The patient then had a DRE, followed by an 
examination with ultrasound.  Under ultrasound guidance 10mls 
of 1% lignocaine was infiltrated around the prostate.  Biopsies 
were then taken.  Following the procedure the patients were given 
500mg metronidazole PR and 3 days of ciprofloxacin 500mg bd 
PO.  The patients were asked to keep a record of any 
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complications, and this data was retrieved by a phone call several 
weeks later. 
Results 
Over the 4 week period 44 patients were given appointments to 
attend for biopsies.  38 biopsies were carried out. 3 were not able 
to be contacted for collation of results.  Biopsies were taken on 
patients aged 46 to 88, the majority aged from 56 to 80.  15 were 
referred direct by the GP, 16 from clinic and 12 from other 
consultants who did not carry out biopsies as part of their 
practice.  Most patients waited from 60 to 100 days. Positive 
biopsy rate was 55%.  22 of the patients had no pain to mild pain 
during the procedure.  8 had moderate and 5 severe pain. Most 
patients found pain was limited to the procedure, although 5 had 
pain for some hours and 7 for longer than 24hrs. 77% had 
haematuria (70% of which settled within a few days), 40% had 
blood PR (70% settled within one day) and 34% haematospermia 
which generally took several weeks to settle.  A small number 
noticed flow problems (although a similar number noted 
improvements), dysuria, or signs of infection.  One gentleman 
suffered a stroke after being off clopidogrel for 14 days and was 
the only patient to require admission due to the procedure.  He 
still had dysphasia several weeks after the stroke. 
Conclusions 
The waiting time for prostate biopsies is far too long.  All should 
be seen within 2 weeks.  However, the waiting list is falling and 
will fall further with the addition of an extra list.  In the 4 week 
period 4 procedures were cancelled because PSAs were not 
checked after being sent from clinic, 1 because he was still on 
clopidogrel, and one patient did not attend.  Furthermore, 2 were 
biopsied who already had tissue diagnoses.  Efficient utilisation 
of appointments is paramount, perhaps with utilisation of a 
database.  Complications were expected and in most cases short 
duration with minimal impact on patients.  The patient who had a 
stroke has prompted discussion about prophylaxis with other 
agents while off anti-platelet drugs and warfarin.  Also most 
patients suffered little pain but those who did may benefit from 
more lignocaine.  Also, a longer acting agent also may reduce the 
numbers of patients with pain post-procedure.  Further audits are 





Effect of very low fat diet on progressive prostate cancer:  
experience from a dedicated clinic 
J. Philip*‡, B. Rogers*, J.S. Grime§, N.J. Parr* 
*Department of Urology, Wirral Hospital CH49 5PE and 




Total dietary fat has been associated with an increased incidence 
and mortality from prostate cancer (CaP). Animal models with 
implanted human CaP cell lines have reported arrest of growth in 
those changed to a very low fat diet (VLFD, <20% fat). We 
offered such a diet to patients with progressive CaP. 
Patients and Methods 
Over 4 years, 22 patients with good performance status 
undergoing either active surveillance (n= 8) or hormonal 
manipulation (n= 14), with biochemical evidence of disease 
progression (2 successive PSA interval rises) adopted VLFD. Fat-
soluble vitamins were supplemented. Patients were reviewed 3-
monthly in a dedicated nurse specialist clinic assessing body 
mass index (BMI), PSA, PSADT, PSA velocity, lipid profile and 
quality of life (QoL). PSA was log transformed as rapid cancer 
proliferation shows log linear growth. 
Results 
Mean age of the patients was 70.1yrs (range 59-80) with a PSA 
range of 3.5 –43.6 ng/ml on commencing VLFD. Mean follow-up 
was 54.8 wks (range 10-152).  16 patients were diagnosed with 
well/ moderately differentiated CaP (Gleason score > 6) with six 
having poorly differentiated CaP (Gleason score <6). There was 
no significant difference in age between the groups.  Patients with 
well/ moderately differentiated showed a significant increase in 
PSA doubling time (PSADT) [p= 0.037] and a reduced PSA 
velocity. Half of the patients with poorly differentiated CaP had a 
prolonged PSADT [Table 1].  BMI showed no significant change, 
but serum cholesterol fell significantly (p<0.05). Patients felt 
subjectively better on VLFD with only two reporting restricted 
QoL. 
Conclusion 
These early results are encouraging and suggest that in men with 
progressive prostate cancer, VLFD results in reduction in the rate 
of PSA progression with significant prolongation of PSADT in 
patients with well/ moderately differentiated CaP. A good QoL is 
also maintained. This merits further multi-centre studies 
involving larger populations. 
 

















































PSA – what’s that doc? 
Priya Agrawal, Jonathan Olsburgh, Jeremy Elkabir 
Northwick Park and St Mark’s Hospitals 
 
Introduction 
There is an increasing incidence of PSA (prostate-specific 
antigen) screening in Primary Care. 
Screening for prostate cancer with PSA is still controversial. 
Thus professional guidelines stress the importance of patients 
making informed decisions, based on an awareness of the 
potential risks and benefits related to testing.   The aim of this 
study was to assess whether new patients attending Rapid Access 
Prostate Clinic had enough understanding to have given informed 
consent for the PSA test to be done.  Did they understand? 
• the role of the PSA test 
• why it was checked in their individual case 
• The implications of a positive PSA test. 
Materials and Methods 
All new patients referred to a special Rapid Access Prostate 
Clinic who had their PSA tested in Primary Care were asked to 
complete a questionnaire, under the supervision of a nurse, before 
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months.  The first 15 questionnaires were used as a pilot study 
resulting in a modified questionnaire.  The patients were asked 
about their knowledge of the PSA test, where from and in what 
form this information had been given to them and their 
occupational background. 
Results 
Of 78 eligible patients, 76 completed the questionnaire.  Only 22 
patients (29%) felt they knew what PSA is.  The other 54 patients 
(71%) were either not sure (12) or did not know (42) what PSA 
is.  72% of these 54 patients could not recall an explanation 
having ever been given, the other 28% was divided amongst 
those that had received a poor explanation (18%) or had forgotten 
the explanation (10%).  Of the 22 patients that felt they knew 
what PSA is, only 58% knew that a high PSA indicated the 
possibility of prostate cancer and only 17% knew of the 
implications of a positive PSA test e.g. TRUS biopsy.   In 46% of 
cases, the GP had offered the test.  In the majority of cases 
(61%), the patient had presented with trouble with their 
waterworks.  Only 12% remember having pre-test counselling 
and only 1 patient received any written information. 
Conclusion 
Men are being tested for prostate cancer in Primary Care without 
informed consent.  The majority do not understand what PSA is, 
what its role is, or the implications of the test and thus cannot 
make an informed decision.  This seems to be irrespective of age 
and occupational background. 
Considering that prostate cancer is estimated to be the most 
common cancer in UK men by 2005, we recommend that there 
should be an increase in patient information made available prior 
to PSA testing.  This information can be written and/or verbal.  
The latter can be from dedicated nurse practitioners, perhaps 
holding prostate awareness clinics in Primary Care.  This has 
significant implications for Primary Care teams; however we 
believe that the benefit of empowering the patient will be reaped 
by both the patients and the health service. 
 
 
Microstaging of carcinoma of the prostate: can biopsy 
findings predict if a tumour is clinically insignificant? 
Alison Yates, Rhidian Hurle, D L Cochlin, H G Kynaston,  
D F R Griffiths 
Departments of Urology, Radiology and Pathology, University 
Hospital of Wales, Cardiff. 
 
Introduction  
There is no consensus as to the correct treatment for a man with 
organ confined prostate cancer. A significant minority of tumours 
detected by PSA screening are clinically insignificant (less than 
0.5ml tumour volume) and offer minimal risk to the patients .  If 
these tumours could be identified then it would be appropriate to 
advise surveillance in these patients.  In theory accurate sampling 
of the gland by a biopsy protocol should allow assessment of 
tumour volume but previous attempts at this have show poor 
predictive value, possibly because either variation in biopsy 
technique or suboptimal histological processing.  The aim of this 
study was to determine if reasonable prediction of tumour size by 
biopsy findings was more likely in the context of consistent 
biopsy practise and meticulous histological processing.  
Method 
Analysis of prostates from 151 consecutive radical prostatectomy 
operations from patients who had previously had sextant or more 
biopsies that had been performed by one of two radiologists 
having a special interest in the biopsy technique.  Biopsy 
specimens has been processed for histology in separate cassettes, 
embedded flat and three levels cut from each block. On average 
15mm of core was examined from each sample.  Radical 
prostatectomy specimens had been fully embedded and the 
volume of tumour estimated from the dimensions of the 
smoothed ellipsoid enclosing the tumour.  Number of positive 
cores, maximum length of adenocarcinoma in a core (MLA), and 
RRP tumour volume had been recorded in each case. 
Results 
There was a strong correlation between both the number of cores 
positive and the MLA with the tumour volume and stage.  27 
(18%) tumours had a volume of 0.5ml or less.  80 cases had a 
MLA on biopsy of ≤4mm and 71 cases had a MLA of >4mm.  
For the cases with a MLA of ≤4mm, 25 (32%) had a tumour with 
a volume of ≤0.5ml. For the cases with a MLA of >4mm, 2 (3%) 
had a tumour with a volume of ≤0.5ml. 29 cases had only a single 
core positive and an MLA of ≤4mm, of these 15 (52%) had 
clinically insignificant tumours. 
Conclusion 
With consistent biopsy technique and meticulous histological 
processing biopsy findings can predict tumour size. This 
microstaging could probably be improved if analysis was limited 
to octant biopsies or more and if PSA level, biopsy Gleason 
grade, and imaging findings are also taken into account.  Future 
reports examining the predictive value of biopsies should give 




Inhibiting Prostate Cancer cell growth by the new technique 
of RNA interference on the emerging gene TSG101. 
N C Borley, G Zhu, I R Hart, G H Muir 
King’s College and St Thomas’ Hospitals, London. 
 
Introduction 
The gene TSG101 was originally defined as a tumour suppressor 
gene, raising the expectation that absence of the encoded protein 
should lead to increased tumour cell growth. There has been 
conflicting evidence as to the gene’s function and the role it plays 
in cell growth. We have specifically inhibited the gene by RNA 
interference to study it’s function. 
Material and Methods  
The technique of RNA interference (RNAi) was used to 
downregulate the gene TSG101 in PC3 (prostate cancer) cells. 2 
controls were used, one with exactly the same cell handling, the 
other with “scrambled” RNA causing interference. Protein levels 
were detected by Western Blotting.   The effect of this on the 
cells was examined with growth curves, colony formation assays, 
invasion and migration assys, and BUDR labeling to examine the 
cell cycle. 
Results  
An approximately 94% selective downregulation at the protein 
level was achieved. This treatment resulted in marked inhibition 
of tumour cell growth. The decreased level of TSG101 protein 
caused partial cell cycle arrest at the G1/S boundary. 
Additionally, RNAi-mediated downregulation of TSG101 
reduced the colony forming capacity of the cells by 
approximately 89%. This treatment did not result in any effect on 
the migration or invasion behaviour of these cells.  
Conclusion  
These results firstly demonstrate the effects of the highly 
powerful technique of RNA interference. They also show that the 
TSG101 gene does not comply with the usual characteristics of a 
tumour suppressor gene that it had been thought to be. But rather 
that its expression may be necessary for activities associated with 
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aspects of tumour growth, having implications for both prostate 
and other cancers. 
 
 
Silencing of the type 1 insulin-like growth factor receptor 
(IGF1R) gene enhances sensitivity of prostate cancer to DNA 
damaging agents through impaired homologous 
recombination 
MA Rochester1,2, BW Turney1,2, SF Brewster2, VM Macaulay1  
1Molecular Oncology Laboratories, Weatherall Institute of 
Molecular Medicine, Oxford, UK; 2Department of Urology, 
Churchill Hospital, Oxford, UK 
 
Introduction 
The IGF1R is overexpressed in prostate cancer, and IGF 
signalling enhances protection from apoptosis. Silencing the 
IGF1R gene by RNA interference leads to impaired survival of 
prostate cancer cells in vitro, and enhanced sensitivity to 
therapies which cause double-strand DNA breaks, but not to 
those which kill by other means, suggesting a link between IGF 
signalling and DNA repair. Previous work in our laboratory has 
shown decreased activation of ATM after IGF1R downregulation 
by antisense. ATM orchestrates the DNA damage response, and 
is the product of the gene mutated in Ataxia Telangiectasia. We 
wished to determine if the differential chemosensitisation in 
prostate cancer cells was a result of altered ATM function, and/or 
a direct effect on DNA repair. 
Materials and Methods 
We used oligofectamine to transfect IGF1R siRNAs or inverted 
sequence controls into two prostate cancer cell lines: DU145 
(androgen-resistant, wild type PTEN), and PC3 (androgen-
resistant, PTEN mutant). ATM function was measured by an 
ATM kinase assay, and response to double-strand DNA breaks 
induced by ionising radiation was assessed by pulsed-field gel 
electrophoresis (PFGE). DNA repair was evaluated directly using 
previously described in vitro assays of non-homologous end-
joining (NHEJ) and homologous recombination (HR). 
Results 
Transfection with 200nM siRNA inhibited IGF1R expression to 
15-20% of control levels. This treatment led to impaired ATM 
activation after 20 Gy irradiation, shown by a kinase assay. 
Pulsed field gel electrophoresis analysis revealed delayed DNA 
repair in siRNA-treated DU145 cells at time-points up to 6 hours 
after irradiation.  IGF1R gene silencing had no effect on NHEJ, 
but in both PC3 (p<0.001) and DU145 (p<0.05) this led to 
approximately 50% reduction in ability to repair by HR. 
Conclusion 
IGF1R targeting by siRNA inhibited ATM kinase activity, in 
keeping with our previous report of impaired DNA damage 
responses following IGF1R downregulation.  The delayed DNA 
repair up to 6 hours after IGF1R silencing shown by PFGE is not 
consistent with an ATM defect alone, since ATM null cells have 
normal kinetics of DNA repair at this time. We showed that 
siRNA treatment had no effect on NHEJ, but led to significant 
impairment of homologous recombination repair in both PC3 and 
DU145, suggesting a link between IGF signalling and the HR 
machinery. These results have implications for the choice of 







A randomised controlled trial of topical glyceryl trinitrate for 
transrectal ultrasound-guided prostate biopsy 
MA Rochester1,2, K Le Monnier2, SF Brewster2  
Molecular Oncology Laboratories, Weatherall Institute of 
Molecular Medicine, Oxford, UK; 2Department of Urology, 
Churchill Hospital, Oxford, UK 
 
Introduction 
Transrectal ultrasound-guided (TRUS) biopsy is the standard 
method of diagnosis of carcinoma of the prostate. Studies have 
shown decreased pain associated with this procedure following 
local anaesthesia. Many patients find anal distension to be the 
most painful part of their procedure, for which local anaesthetic 
infiltration has little benefit. Topical glyceryl trinitrate (GTN) 
paste is commonly used for the treatment of anal fissure. The 
mechanism of action is through reduced anal sphincter tone. We 
evaluated the efficacy and tolerance of topical 0.2% GTN paste 
versus placebo to reduce pain associated with TRUS biopsy.  
Materials & Methods 
Between October 2003 and April 2004, 134 consecutive patients 
referred for first prostate biopsy were randomised to receive 
either topical 0.2% GTN paste or placebo 30 minutes prior to 
biopsy. Participants completed a 10 point visual analogue pain 
score following the procedure. Pulse and blood pressure were 
recorded before and during the procedure.  
Results 
The mean age of the patients was 68.5 years for the GTN group 
and 68.8 for placebo. There was a significant decrease in mean 
pain score in the GTN group compared with placebo (3.7 versus 
4.8, p=0.0016). There were no significant changes in pulse or 
blood pressure between the groups. 6 patients (10%) in the GTN 
group complained of headache.  
Conclusions 
Topical GTN paste is an effective and well tolerated method of 
reducing pain associated with transrectal ultrasound guided 
prostate biopsy. It is a safe and easy to use alternative to other 




Pathologists estimation of percentage carcinoma in radical 
prostatectomy specimens – A literature review and a grid 
method for calculation 
Clare Verrill, Paul Strike, Clare Fuller. 




We reviewed the literature in an attempt to determine whether 
volume of prostatic adenocarcinoma is an independent prognostic 
variable for disease recurrence after radical prostatectomy.  
Percentage surface area of gland infiltrated by adenocarcinoma in 
radical prostatectomy specimens is routinely recorded within 
proforma standardised reports at Salisbury District Hospital.  It is 
not a data item within the RCPath minimum dataset for prostate 
cancer.  We wished to find an easy, reliable and time efficient 
method of measuring percentage surface area of tumour.   
Materials and Methods 
We compared 3 methods of measuring percentage surface area of 
gland infiltrated by adenocarcinoma in radical prostatectomy 
specimens; using a microscopic 1mm2  grid counting, 
macroscopic 10mm2 grid counting and visual estimation by 
pathologist without aid of a grid.  We reviewed the literature 
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Results 
The microscopic 1mm2 grid, shown to be as accurate as computer 
assisted morphometry (Humphrey et al, Mod Pathol 
1997;10:326-33) took 90 minutes per case.  The macroscopic 
10mm2 grid took 10 minutes per case.  The 2 methods gave 
similar results.  Pathologists unaided by a grid were up to 25% 
out in their estimation. 
Literature review showed that many of the published studies did 
not contain enough subjects to enable reliable interpretation of 
the results.  Of the studies containing sufficient subjects, 2 
showed that percentage carcinoma is an independent predictor of 
recurrence (Ramos et al, J Urol 2004; 172: 137-140 and 
Carvalhal et al, Cancer 2000; 89:1308-1314) and 2 showed that 
tumour size (as determined by alternative methods) is an 
independent prognostic factor (Renshaw et al, Anat Pathol 
1999;111:641-644 and Stamey et al, JAMA 1999;281:1395-
1400).  1 showed that tumour size was not an independent 
prognostic factor (Epstein et al, J Urol 1993; 149:1478-1481).  
Conclusion 
Literature review has found evidence that percentage surface area 
of carcinoma is an independent prognostic factor for disease 
recurrence after radical prostatectomy.  We therefore recommend 
that this measurement is an essential data item for inclusion in 
histopathology reports.  We have described a quick method 
which provides an accurate measurement and could be used in 
everyday practice.  
 
 
Palliative pelvic exenteration for advanced prostate cancer.  
S B Ganta, H Yamamoto, DA Ashdown, DMA Wallace.  
University Hospital Birmingham, Birmingham, UK.  
 
Introduction  
Locally recurrent prostate cancer is debilitating with significant 
local symptoms. Pain associated with rectal involvement of the 
prostate disease is difficult to palliate using conventional 
techniques. We describe 6 patients who underwent a pelvic 
exenteration for palliation of advanced prostate cancer.  
Materials and Methods 
We retrospectively reviewed the data of six patients who 
underwent palliative exenteration and diversion for prostate 
cancer between 1986 and 2002. Patients were selected for total 
pelvic exenteration based on clinically advanced prostate cancer 
with intractable symptoms despite hormone treatment and 
radiotherapy. The median follow up was 25.7 months (range 
12.1-47.2 months). Data were collected regarding cancer therapy, 
pain requirements prior to surgery, complications, symptom free 
survival and overall survival. 
Results 
The mean age prior to surgery was 68.4 years (range 62-78 
years). The mean duration between diagnosis and operation was 
5.1 years (range 4.3-6.9). The mean preoperative PSA was 31 
(range 0.1-173). All patients had had radiation therapy to the 
pelvis and androgen deprivation treatment. One patient had prior 
radical retropubic prostatectomy. Surgery included total pelvic 
exenteration followed by an end colostomy and ileal conduit 
urinary diversion. The rectum was spared in one patient. There 
was no post operative mortality. The median symptom free 
survival was 12 months (range 4-36 months). The median overall 
survival was 25.7 months (range 12.1-47.2 months). Three 
patients died of disease progression and two died of other causes 




Pelvic exenteration effectively palliated symptoms of advanced 
local recurrence for a median period of 12 months with 
acceptable post operative morbidity. It is an effective treatment in 




‘Laparoscopic’ extraperitoneal retropubic prostatectomy; the 
Birmingham experience. 
S B Ganta, D Ashdown, H Yamamoto A Doherty. 
University Hospital Birmingham, Birmingham  
 
Introduction: 
Laparoscopic techniques for many urological procedures are now 
well established.  Radical prostatectomy performed with minimal 
invasive surgery by an extraperitoneal route overcomes the 
limitations and complications entering the peritoneum and is 
similar to the most commonly performed open operation. 
Patients and methods:  
67 patients with clinically organ prostate cancer underwent a 
‘laparoscopic’ extraperitoneal radical prostatectomy performed 
by one surgeon between  June 2003 and November 2004. A 
modified ‘Stolzenburg technique’ 1 was utilized with nerve-
sparing and a more reproducible bladder neck and urethral 
dissection. Prospective data collection of the grade, stage and 
volume of cancer, co-morbidity, intra and post operative 
complications.   
Results:  
The median (range) age was 65.2 (46-73) years, median PSA 7.0 
(2.5-16) ng/mL, Gleason sum 7 (3+4), operative time was 240 
(135-391) min, blood loss 375 (100-1800) mL and hospital stay 
after LRP 4.2 (2-26) nights. Nerve preservation was performed in 
28% of patients. One patient required transfusion. Three patients 
were converted to an open procedure. There were six 
complications, rectal injury in two cases (one required a 
colostomy and the other had a successful intra-operative 
laparoscopic repair). Bladder neck stenosis, persistent urinary 
leak from drain, pulmonary embolus and paralytic ileus. The 
positive surgical margin rate reduced to 18% in the last 20 
patients. Follow up was a mean 7.2 months (1-17.6). By 3 months 
84 % of patients were pad-free. There have been two biochemical 
failures.  
Conclusion:  
Learning curve relates to perfecting a technique, training 
assistants and making best use of the equipment. Several 
technical modifications have been introduced. Prospective data 
collection allows for early identification and correction of 
problems and improvements in outcome. In addition to the 
standard benefits of minimally invasive surgery, the 
extraperitoneal approach mimics the open approach and offers 
improved visualization. We believe that this technique is safely 




The IGF1R/IRS1 axis and PI3K/PKB signalling in prostate 
cell lines 
Jennifer C. Spalton, Norman J. Maitland & R. Michael Sharrard,  
University of York 
 
Introduction 
Insulin-like growth factor 1 (IGF1) signals through the IGF1 
receptor (IGF1R) to stimulate phosphatidylinositol 3-kinase 
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(PI3K) activity and subsequent phosphorylation and activation of 
protein kinase B (PKB). Insulin receptor substrate 1 (IRS1) is an 
important mediator of PKB activation as it acts as an adaptor 
between the activated IGF1R and PI3K. The PKB pathway is of 
particular interest with respect to prostate cancer as elevated 
plasma IGF1 levels are thought to have a positive correlation 
with the disease (Chan et al. Science 1998; 279: 563-566 ; 
Chokkalingam et al. The Prostate 2002; 52:98-105), and 
deregulation of the PKB pathway, through the loss of the PTEN 
tumour suppressor gene, is one of the most common events in 
prostate cancer progression (Cairns et al. Cancer Res. 1997; 
57:4997-5000; Li et al. Science 1997; 275:1943-1947). 
Materials and methods  
The expression and activation of key components of the PKB 
pathway were analysed in five prostate epithelial cell lines – non-
malignant PNT2C2 and PNT1a, early tumour P4E6, and the 
LNCaP and PC3 metastatic cancer cell lines. Reverse 
transcription-PCR, Real-time (quantitative) PCR, 
immunoprecipitation and western blotting were used to assess the 
levels of expression of IGF1R and IRS1 in the prostate cell lines. 
The effects of IGF1 and the PI3K inhibitor LY294002 on IRS1 
protein levels and PKB activation were determined by western 
blotting, using specific antibodies against IRS1, Phospho-PKB 
(Thr308 and Ser473), and total PKB. siRNA was used to 
determine the impact of IGF1R and IRS1 inhibition on PKB 
activation.  
Results  
Metastatic prostate cancer cell lines show reduced expression of 
IGF1R at both the mRNA and protein level when compared with 
the non-metastatic cell lines. The lack of full-length IRS1 protein 
in LNCaP was found to be caused by a single base deletion that 
results in the premature termination of the sequence. IRS1 protein 
levels are differentially regulated in the cell lines: IGF1 induced 
degradation of IRS1 protein in PNT2c2, PNT1a and P4E6, but 
this was not observed in PC3. PKB was still activated on IGF1 
treatment even when the expression of IGF1R or IRS1 was 
inhibited by siRNA.  
Conclusions  
These results suggest that deregulation of IRS1 may contribute to 
the constitutive activation of PKB during prostate cancer 
progression through a positive feedback loop. Our results also 
highlight the potential for crosstalk between cell signalling 




Genotype and expression profiling of prostate cancer stem 
cells 
Steven D. Bryce1, Anne T. Collins1, Mike J. Stower2,  
Norman J. Maitland1 
1YCR Cancer Research Unit, Department of Biology, University 
of York, York YO10 5DD 
2Department of Urology, York District Hospital, York YO31 8HE 
 
The target cell for malignant conversion in prostate cancer 
remains to be definitively identified. The cancer stem cell model 
postulates that mutations occur only in stem cells.  
We have previously shown that prostate stem cells express high 
levels of integrin α2β1 and the haematopoetic stem cell marker 
CD133. These cell surface markers can be exploited to select cell 
populations highly enriched for stem cells.  
We have recently identified that such α2β1High/CD133+ cells 
comprise a small quantity of cells derived from prostate cancers 
(on average <0.01%). Furthermore these cells are maintained at a 
constant proportion in the primary cell cultures obtained from 
these tumours. As part of our ongoing studies to characterize 
these cancer stem cells we are using Affymetrix Mapping 10K 
2.0 SNP arrays to derive comprehensive and detailed genotypes 
from the isolated tumour α2β1High/CD133+ cells and matched 
lymphocyte controls. This in depth data is used to build up 
patterns of genomic loci loss in the cancer stem cells. In addition 
we are obtaining comprehensive gene expression profiles, using 
Affymetrix U133 plus 2.0 GeneChips, from the same cells.  
This will enable us to map characteristic regions of gene loss and 
identify with fine precision (sub mega-base resolution) novel 
losses in clonal cell populations. The linking of comprehensive 
LOH profiles to the gene expression profiles will generate a 
unique depiction of the genetic changes underpinning this the 
development of this disease and provide solid evidence that these 




Alterations in the expression and activation pathways of 
Protein Kinase B and its isoforms in the progression to 
metastasis of human prostate cancer 
R. Michael Sharrard and Norman J. Maitland,  
University of York 
 
Introduction:  
Progression to invasiveness and metastasis in epithelial tumours 
is characterised by cell growth and survival independent of 
growth factors (GFs) and cell-cell and cell-matrix contact.  These 
functions are modulated by Protein Kinase B (PKB/Akt), 
activated by PIP3 generated by phosphatidylinositol 3-kinase 
(PI3K).  Enhanced survival of metastatic prostate tumour cells 
has been linked to deregulation of PKB activation through loss of 
the tumour suppressor protein PTEN, which normally functions 
as an antagonist to PI3K by degrading PIP3.  Protein Kinase B 
has multiple isoforms encoded by three separate genes (AKT1, 
AKT2 and AKT3), though until recently little has been 
established about the regulation and role of these isoforms.  In 
this report we examine the expression of three major isoforms of 
PKB and their activation by growth factors during the 
progression to metastasis of prostatic cancer. 
Materials and methods:  
PNT2 and PNT1a (prostatic non-tumour epithelial), P4E6 (early 
prostatic tumour) and LNCaP and PC3 (metastatic prostate 
tumour) cell lines were grown in the medium containing serum, 
then transferred to serum-free medium overnight.  10µM 
LY294002 (PI3K inhibitor) or vehicle (DMSO) were added for 2 
hours, followed by treatment with 5 ng/ml EGF or IGF1. Cells 
were then harvested and analysed by Western blotting for 
expression and phosphorylation of total PKB or its specific 
isoforms.  Cells were also transfected with expression constructs 
encoding the three PKB isoforms and their capacity to activate 
the different isoforms in the presence or absence of GFs and 
LY294002 was analysed by Western blotting and 
immunocytochemistry. 
Results:  
Using these cell lines, we previously demonstrated that prostate 
tumour cells show reduced dependence of PKB/Akt activation on 
GFs or substrate adhesion, concomitant with enhanced sensitivity 
to the PI3K inhibitor LY294002.  Our present investigations 
show that the different cell lines express different profiles of PKB 
isoforms, and the relative and absolute levels of these isoforms 
determines the phosphorylation status and total PKB activity 
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Overexpression of exogenous PKB isoforms results in their 
hyperphosphorylation at serine 473 and also causes increased 
phosphorylation of endogenous PKB at this residue.  
Unexpectedly, this hyperphosphorylation was both independent 
of GF stimulation and resistant to inhibition by the PI3-kinase 
inhibitor LY294002. This indicates one mechanism by which 
overexpression of individual PKB isoforms may lead to increased 
activity in the other isoforms of this signalling kinase. 
Conclusion:   
Prostate cancer progression involves complex alterations to 
signalling pathways regulating proliferation and survival. The 
elucidation of the mechanisms by which alterations in the pattern 
of PKB isoform expression may lead to escape from normal 
dependence on growth factor- and cellular adhesion-dependent 
signalling provides a further step in understanding the basis of 
this progression. The possibility that altered expression of 
individual PKB isoforms may determine specific patterns of 
escape from normal growth constraints offers the exciting 
possibility that drugs designed against these isoforms may permit 
increased specificity of therapeutic targeting in the treatment of 
prostate cancers and their metastases. 
 
 
High Intensity Focused Ultrasound (HIFU) for prostate 
cancer: The UK experience 
I M Campbell, G N Collins, A A Adeyoju, R J Brough,  
P H O’Reilly, S C W Brown. 
Stepping Hill Hospital, Stockport, UK – On behalf of the North-
West Uro-oncology Research Group 
 
Introduction 
High intensity focused ultrasound produces accurate tissue 
destruction of a target area without damaging the intervening 
tissues. It is emerging as an alternative treatment for several 
forms of cancer, including kidney, breast, bone and prostate. 
Stepping Hill Hospital is the first unit in the U.K. to introduce 
HIFU for the treatment of prostate cancer.  
We describe the technique, practical aspects, efficacy and patient 
tolerability of HIFU treatment for prostate cancer in our own UK 
population. 
Materials and Methods 
A pilot study of 30 patients is in progress. The inclusion criteria 
are: biopsy proven prostate cancer, a PSA of <20ng/ml, a prostate 
volume of <40mls at baseline investigations, localized disease 
(T1/T2) and no contraindications to a 3-hour general or spinal 
anaesthetic. All are deemed to be unsuitable for radical surgery, 
through patient choice, anaesthetic or surgical factors.  The 
patients receive either a general or a spinal anaesthetic. A 
preliminary channel TURP is performed. HIFU prostatectomy is 
then undertaken with the Ablatherm® device using a 3MHz 
transrectal probe. Serum samples are taken at baseline and at 
intervals post operatively to measure inflammatory markers, 
cardiac toxicity and PSA response. The flow rate and post-void 
residual are measured in all patients pre and post operatively. 
Quality of life issues are evaluated using IPSS and the UCLA 
prostate cancer questionnaire. 
Results 
Techniques, practical aspects, efficacy, governance and 
evaluation are described in detail.13 patients have been treated 
and their characteristics are as follows. Mean age 69 years, 
Gleason 3+3 (median) and a mean volume of 27cm3. All patients 
had stage 1 or 2 disease with a mean PSA of 7.3ng/ml (range 3.4 
– 17.3). 9 patients have reached 3 months follow up. There have 
been no intra-operative complications. The majority of patients 
were discharged on day 1 post operatively. All patients showed a 
PSA response with 5 out of 8 patients who received a complete 
treatment achieving a PSA less than 1.0 at 3 months. All patients 
had an elevated CRP post operatively, however this resolved in 
the majority by 1 week. 1 patient had an elevated Troponin T as a 
result of a pulmonary embolism. The QOL and IPSS scores had 
improved or remained static in 5 out of 6 responses so far.  
Conclusion 
This preliminary report of our very early experience suggests 
good tolerability and a promising initial PSA response. 
 
 
Do type I receptor tyrosine kinases drive hormone 
refractory prostate cancer? 
Dr J Edwards, Miss A F. Munro, Dr B Dunne, Miss C Pirrett,  
Dr J. M.S. Bartlett. 
Glasgow Royal Infirmary and University of Glasgow 
 
Introduction 
Relapse during androgen withdrawal therapy is a major cause 
of prostate cancer morbidity and mortality. Androgen receptor 
mutations (6-10%) and amplifications (20-30%) may explain 
relapse in some cases, however in approximately 70% of cases 
alternative mechanisms must be invoked. Our evidence 
suggests that type I receptor tyrosine kinases play a role in the 
development of hormone refractory prostate cancer. 
Materials and Methods 
Protein expression and activation of type I receptor tyrosine 
kinases was determined by immunohistochemistry in a cohort of 
matched tumour pairs (one taken before and one after hormone 
relapse) from 65 prostate cancer patients.  Five antibodies were 
used, EGFR (Zymed), HER2 (DAKO HercepTestTM), 
phosphorylated EGFR (Cell Signalling), phosphorylated HER2 
(Neomarkers) and EGFR VIII (Zymed).  Detection and 
visualisation and was achieved using the LSAB+ kit (DAKO 
Cytomation) and DAB  (Vector Laboratories). Two independent 
observers using a weighted histoscore method scored each 
section. 
Results 
Tumour expression rates for EGFR and phosphorylated EGFR 
were low in both hormone sensitive (36% and 9%) and 
hormone refractory tumours (36% and 11% respectively), with 
no significant increase in expression or activation with the 
development of hormone refractory prostate cancer.  Whilst 
expression rates were higher for HER2, phosphorylated HER2 
and EGFR VIII no significant increase in median expression 
was observed with the development of hormone refractory 
prostate cancer (48% to 67.3 %, 43% to 42% and 100% to 
100%).  
Intriguingly, however, those patients whose tumours expressed 
low levels of phosphorylated HER2 in their primary tumour 
relapsed significantly earlier than those who expressed high 
levels of phosphorylated HER2 (0.039, Kaplan Meier). 
By using matched tumour pairs we were able to identify patients, 
for each protein, whose tumours showed an increase in protein 
expression with the development of hormone escape, no change 
and or a decrease in protein expression.  A change in protein 
expression was defined as an increase or decrease greater than the 
95% confidence interval for inter-observer variation when 
comparing expression between pre and post hormone relapse 
cases. 
Using this method time to death post hormone relapse, was 
markedly decreased for those patients with an increase in HER2 
expression (15.4% of cases,0.004, Kaplan Meier), and an increase 
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in EGFR expression (7.7%, p=0.0004, Kaplan Meier), but not 
with phosphorylated HER2 (26.8%), phosphorylated EGFR 
(6.9%) or EGFR VII (10.3%)I.  Almost 1/4 (23.1%) of cases 
showed increased HER2 or EGFR expression at hormone relapse, 
this was associated with a significant reduction in time to death 
from hormone relapse (3.00(1.75-4.25) versus 1.33(0.86-1.80),    
p = 0.0002, Kaplan Meier).  
Conclusion 
Increased expression of HER2 or EGFR appears to influence 
progression to hormone refractory prostate cancer in about a 
quarter of cases since a rise in HER2/EGFR expression at 
hormone relapse is associated with a significant reduction in time 
to death. These findings support the development of EGFR/HER2 
targeted therapies in hormone refractory prostate cancer. We have 
demonstrated, using a carefully characterized patient cohort, that 
the EGFR/HER2 pathway may represent one of a number of 
independent routes to hormone escape in prostate cancer. 
 
 
Transperitoneal or extraperitoneal laparoscopic radical 
prostatectomy: does the approach matter? 
T. Gianduzzo, C. Chang and C. Eden. 
North Hampshire Hospital, Basingstoke. 
 
Introduction 
Extraperitoneal laparoscopic upper tract surgery is associated 
with several advantages over its transperitoneal counterpart but is 
technically more difficult to perform. The situation with regard to 
laparoscopic lower tract surgery remains unclear. 
Methods  
The results of 100 cases of transperitoneal laparoscopic 
prostatectomy (TLRP) and 100 cases of extraperitoneal 
laparoscopic prostatectomy (ELRP) performed for ≤T3aN0M0 
prostate cancer were compared. 
Results 
In-patient: mean values in TLRP & ELRP patients for operating 
time=239 & 191 (P <0.0001) minutes, blood loss=311 & 202 
(P=0.02) ml, hospitalisation=3.8 & 2.6 (P <0.0001) nights. 
Out-patient: mean values in TLRP & ELRP patients for follow-
up=24.5 & 7.2 months, + margin=16% & 16%, pad-free rate at 1 
year=90% & 96%, erection rate at 1 year=61% & 82%. 
Conclusion 
ELRP is superior to TLRP with respect to operating time, blood 
loss and hospitalization. Early oncological results are identical. 
Longer follow-up is needed to demonstrate differences in 
functional and results. 
 
 
Multi-marker Quantitative RT-PCR Based Analysis of Blood 
and Bone Marrow in Prostate Cancer Patients 
David Ross1,3, Claire Hart1, Iain McIntyre4, Vijay Ramani2,  
Mick Brown1, Noel Clarke1,2,3 
1 ProMPT Genito Urinary Cancer Research Group, Cancer 
Research UK Paterson Institute, Manchester, UK 
2Department of Urology, Christie Hospital NHS Trust, 
Manchester, UK 
3Department of Urology, Salford Royal Hospitals NHS Trust, 
Salford, UK 
4Department of Urology, Central Manchester Hospitals NHS 
Trust, Manchester, UK 
 
Introduction 
The natural history of prostate cancer (CaP) is difficult to predict. 
The key to appropriate treatment is detection of extra-prostatic 
disease. We have evaluated a quantitative reverse transcriptase 
polymerase chain reaction (qRT-PCR) assay using a combination 
of established and novel molecular markers to detect small 
numbers of circulating prostatic cells in peripheral blood (PB) 
and bone marrow (BM). 
Materials and Methods  
Five nucleotide primers and probes were designed and optimised 
for PSA, prostate specific membrane antigen (PSMA), prostate 
stem cell antigen (PSCA), human kallikrein 2 (HK2) and DD3 
using the LNCaP prostate cancer cell line. In vitro assay 
sensitivity was calibrated using dilutions of LNCaP cells in 
female PB. The PAXgene blood RNA system was optimised for 
PB and BM collection, storage and RNA isolation. Marker 
expression was quantified in serial dilutions and limits of 
detection determined using qRT-PCR. DD3 was also quantified 
using a plasmid construct. Paired PB and BM samples were then 
assayed from patients with well characterised CaP and compared 
with disease free controls. 
Results  
All five gene products were detected and quantified in LNCaP 
cells. Additionally, DD3 was detected in RNA derived from 
prostate biopsy samples. In vitro limits of detection were 1 
LNCaP cell/105 nucleated cells for PSA and PSMA, 1:104 for 
PSCA and 1:103 for HK2. The DD3 assay could detect 100 copies 
of plasmid derived RNA/106 nucleated cells. Samples from 102 
men with CaP and 38 healthy controls were evaluated. The 
qualitative results are presented below, detailing the percentage 
of samples reading positive for each marker in patients with 
different disease stages. Quantitation and threshold calibration of 
single markers levels and combinations of levels is currently 
awaited. 
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Conclusions  
We have developed a multi-marker qRT-PCR assay which can 
reliably detect the presence of spiked prostate epithelial cells in 
PB samples in vitro. Preliminary qualitative clinical data 
highlights the need for such a quantitative multi-marker 
technique the true clinical utility of which will be determined 
through further statistical modelling. 
 
 
Prostatic biopsies in the over 80’s: crucial or cruel? 
Bott SRJ, Foley CL, Bull MD, Reddy CJ, Freeman A,  
Langley SEM 
And contributing surgeons, nurse specialists and pathologists: 
Davies JH, Emberton M, Kirby RS, Millroy EJG, Montgomery 
BS, Morgan RJ, Nigam AK, O’Donoghue EPN, Palfrey EL, 
Shridhar P, Pietrazic M, Higgins D, Denham P, Mannion E, 
Parkinson MC. 
The Royal Surrey County Hospital, Frimley Park Hospital and 
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Introduction:  
Prostate cancer is considered a tissue diagnosis commonly based 
on biopsy cores. Standard prostate biopsy has a reported minor 
complication rate of 60-79%, major complication rate of 0.4-
4.4% and the need for hospitalisation in 0.4-3.4% of men 
(Norberg Eur.Radiol. 1996; 6: 457, Aus Br.J.Urol. 1996; 77: 851, 
Rietbergen Urology 1997; 49: 875, Rodriguez J Urol. 1998; 160: 
2115-20) and infection risk increases with age (Lindert J Urol. 
2000; 164: 76). This study examines whether prostatic biopsies 
are necessary in all men aged 80 or above. 
Methods:  
The pre-biopsy PSA, the DRE, the biopsy findings and staging 
bone-scan results of all men aged ≥80 years who underwent 
prostatic biopsies between 2000-2003 were reviewed. All biopsy 
samples had been examined in one of three histopathology units 
and thirty-three consultant urologists contributed.  
Results:  
211 men ≥ 80 years were identified, of whom 163(77%) had 
biopsy proven prostate cancer. 100% of 29 men with PSA ≥100, 
98% of 47 with PSA ≥50, 97% of 77 with PSA ≥30 and 92% of 
102 with PSA ≥20ng/ml had biopsy cores containing cancer. 63% 
of men with PSA <20ng/ml had cancer on biopsy. In men with 
cancer and a PSA ≥30ng/ml, 92% had Gleason grade ≥7and 93% 
were treated with antiandrogen therapy and /or pelvic 
radiotherapy. In all men with cancer the DRE was abnormal in 
91%, the mean number of positive cores was 59% and the bone-
scan was positive in 18%. The DRE was abnormal in 77% of men 
with benign biopsies.  
Conclusions  
In men ≥ 80 years with a PSA ≥30ng/ml, at least 97% had 
prostate cancer, over 90% of these men had high-grade disease 
and nearly all men with cancer received active treatment. The 




Sensitive and non-invasive diagnosis of Prostate Cancer using 
E2F3 quantitative RT-PCR 
C. P. Pipinikas1, S. B. Nair1, 2, K. I. Konstantinou3, R. S. Kirby2, 
N. D. Carter1 and C. D. Fenske1  
2St George’s Hospital and 1Medical School, London SW17, 
3Department of Epidemiology and Public Health, Imperial 
College, Faculty of Medicine, London W2 1PG 
 
Introduction 
Reverse transcriptase-polymerase chain reaction (RT-PCR) is a 
sensitive molecular technique capable of detecting prostate cells 
in peripheral circulation. Quantitative RT-PCR (qRT-PCR) is an 
expansion of this technique, used to look at levels of gene 
expression. Potential markers for prostate cancer (CaP) have been 
assessed using qRT-PCR with the aim of more accurate 
diagnosis. E2F3 gene, a member of the E2F family of cell cycle 
regulatory transcription factors (Oeggerli et al. Oncogene 2004; 
23:5616-23) has been shown to be overexpressed in CaP, 
controlling proliferation rates and dictating CaP aggressiveness 
Furthermore E2F3 directly modulates the expression of the EZH2 
gene, which also controls cellular proliferation and is up-
regulated in CaP (Foster et al. Oncogene 2004; 23: 5871-9).  
Both genes, therefore, are potentially excellent candidate markers 
for CaP diagnosis.   Using relative quantitative RT-PCR (qRT-
PCR), E2F3 and EZH2 expression was analysed as potentially 




Total RNA was extracted in quadruplet from blood taken from 
110 patients. cDNA synthesis was carried out, followed by qRT-
PCR using E2F3 and EZH2 gene specific primers and the 
LightCycler™ (Roche).  
Results 
Relative qRT-PCR for E2F3 was carried out on four distinct 
patient groups, based on detailed clinicopathological information. 
E2F3 expression showed highly significant differences between 
all patient groups (P<0.001): a 39-fold increase was found in the 
localised prostate cancer group (LocCaP: n=51;mean= 4.67) 
compared to benign prostatic hyperplasia group (BPH: n=8; 
mean=0.12).  Levels in the metastatic prostate cancer group 
(MetCaP: n=23; mean =1.64) were lower than the LocCaP group, 
but still 14-fold higher than the BPH group levels.  Of particular 
interest was the radical prostatectomy group (RP: n=18, mean = 
4.08), which showed levels of E2F3 expression similar to those 
of the LocCaP group.  This would indicate the presence of 
tumour cells in peripheral circulation, suggesting undetected 
micrometastases.  No E2F3 expression was detected in male 
control samples (n=10).  Preliminary results for EZH2 showed a 
similar expression profile to that of E2F3, with significant up-
regulation in CaP patients.   
Discussion 
The expression of E2F3 has been shown to be highly up-
regulated in prostate cancer.  Results show that it can be used as a 
marker in accurate diagnosis of CaP using the non-invasive, 
sensitive technique of qRT-PCR.   
E2F3 has been shown to directly modulate the expression of 
cellular proliferation genes, including EZH2, and is linked to 
pRB, a cell cycle protein (Huang et al Nat Genet 2003; 34:226-
230).  It is therefore possible that the pRB-E2F3-EZH2 axis 
represents an underlying molecular mechanism involved in the 
development of CaP. This offers the potential of specific 
treatment based on patient’s gene expression profile. 
 
 
Prostate Cancer - The MALE Perspective 
Michael G. Clarke, JRM Wilson, JD Graham, RP MacDonagh 
Taunton & Somerset Hospital, Taunton 
 
Introduction 
It is essential when making judgements regarding the 
management of prostate cancer, that clinicians utilise both patient 
choice and life expectancy, in addition to the available clinical 
parameters. However estimations of life expectancy, based on co-
morbidity, are often inaccurate and inconsistent. Whilst validated 
co-morbidity scores exist, these are often disease-specific and 
cumbersome to use. We therefore aimed to develop a computer 
software program that would enable clinicians (or other members 
of the multidisciplinary team) to accurately calculate an 
individual patient’s life expectancy on the basis of their co-
morbid factors, with the potential for use in the clinical and MDT 
setting. 
Materials & methods 
In collaboration with a professional actuary, actuarial tables were 
used in association with the ‘numerical rating system’ to derive 
mortality ratios. These evidence-based actuarial mortality ratios, 
which are used by the insurance industry and are continually 
updated in line with the available medical literature, are 
calculated on the basis of a patient’s age, smoking habit and co-
morbidity. They can therefore provide an accurate method of life 
expectancy assessment in patients with multiple co-morbid 
factors. 17 medical conditions were chosen, since they 
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significantly impacted on life expectancy and were relevant to 
>90% of patients seen in general urological outpatients clinics.  A 
user-friendly computer program was then designed, in association 
with professional computer programmers, to enable easy access 
to this information via a PC and/or PDA. Using hypothetical 
patient scenarios, the program was tested to ensure ease of use 
and accuracy of results. 
Results 
A computer software model was developed: Measure of 
Actuarial Life Expectancy (MALE). This was not only found to 
be user-friendly but also derived accurate results consistent with 
the actuarial tables integral to the program. The inputting of 
patient information, using the patient’s case notes, enabled the 
calculation of 1) Predicted life expectancy (average number of 
years an individual of a given age is expected to live), 2) 
Percentage chance of survival to 5 years, 10 years and 15 years, 
3) Graphical presentation of these results. The option to save 
these results and print reports was available. (NB Screenshots 
and/or the computer program itself will be available if presented) 
Conclusion 
This computer software provides an accurate and objective 
measure with potential for use in outpatient clinics and 
multidisciplinary team meetings. Research is ongoing to assess 
the impact of this life expectancy information on the management 
decisions of consultant urologists regarding patients with prostate 
cancer, as well as the patients’ understanding of and their desire 
to know this information.  
 
 
Functional analysis of domain specific zero function androgen 
receptor mutations in prostate epithelial cells 
Richard Birnie and Norman J. Maitland 




Androgen ablation is a powerful therapy for prostate cancer until 
the disease undergoes a transition to the hormone refractory form. 
In a subset of disease this may be achieved by mutation of the 
androgen receptor gene. Mutations are known to occur 
throughout the AR gene suggesting multiple mechanisms may 
exist to achieve androgen independence. We chose two 
previously characterised androgen receptor mutations found in 
prostate cancer to investigate the role of different protein domains 
in ligand sensitivity and AR trafficking. Specifically, a DNA 
binding deficient mutant (AR-C619Y) and ligand binding 
deficient mutant (AR-C784Y). 
Materials and Methods: 
Site directed mutagenesis PCR was used to introduce point 
mutations into the androgen receptor cDNA. Wild type or 
mutated androgen receptor cDNA in the episomal vector pCEP4 
was transiently transfected into either PNT1A or PC3 prostate 
epithelial cell lines in which  AR is under the control of a CMV 
promoter. Protein expression and localisation was assessed by 
western blot and fluorescent immunocytochemistry respectively 
48h post transfection, during which period cells were exposed to 
hormones for the last 18h. The transactivation capacity of the 
different mutants was analysed using flow cytometry to measure 
activation of a promoter-EGFP reporter construct (PSA/Pb-
EGFP). 
Results: 
Western Blot analysis showed that all three forms of AR are 
expressed at the predicted molecular weight in non-malignant 
PNT1A cells and in PC3 prostate cancer cells. The wild type 
protein is expressed at low levels in the absence of ligand in both 
cell lines and expression is increased by addition of DHT. The 
AR-C619Y and AR-C784Y mutants are expressed at high levels 
in PNT1A but show evidence of protein degradation whereas 
these proteins are constitutively low in PC3 cells. In the absence 
of ligand all three forms of AR show cytoplasmic localisation. 
When treated with DHT wild type AR translocates to the nucleus 
in both PNT1A and PC3 cells as does the AR-C619Y mutant. In 
the presence of the anti-androgen bicalutamide wild type AR and 
AR-C619Y undergo partial translocation to the nucleus while the 
AR-C784Y mutant remains cytoplasmic regardless of treatment. 
Wild type androgen receptor is able to induce EGFP expression 
in response to DHT treatment in a dose dependent manner in both 
PNT1A and PC3 cells, this activity is partially inhibited by 
bicalutamide. The AR-C619Y and AR-C784Y mutant androgen 
receptors are unable to transactivate the reporter construct. 
Conclusion: 
Transcriptional transactivation by the androgen receptor can 
viewed in terms of distinct functional modules directly related to 
the receptor structural domains. Disrupting the function of a 
single module can block the function of the entire receptor even if 
the other modules remain intact. We have shown that mutation of 
either the DNA binding or Ligand binding domain independently 




Isoliquiritigenin, a botanical COX inhibitor, suppresses 
prostate cancer cell proliferation, down regulates      
androgen-receptor and PSA protein expression 
Sophie Chen1,2, J. Gao1,2, H. Dorota Halicka1  
1Department of Medicine, New York Medical College, Valhalla, 
NY 10595,  
2NovaSpes Research Lab, Hawthorne, NY 105322 
 
Introduction 
PC-SPES was a proprietary composition, comprised of refined 
extracts from 7 herbs used in traditional Chinese medicine plus 
Saw Palmetto extract.  In several trials and experiments since 
1997 its potent anti-prostate cancer activity was confirmed.   In 
the continuing effort to isolate and investigate its biologically 
active components and mode of action we have identified further 
active compound Isoliquiritigenin (ISL).  This report presents our 
findings of the in vitro mechanism of ISL.  ISL is a chalcone 
belonging to the flavonoids family contained in the licorice root 
(one of the eight botanical components of PC SPES).  It had been 
reported for estrogenic, anti-inflammatory and anti free radical 
activities.  However its molecular action on prostate cancer was 
unknown. 
Materials and Methods 
MTT cell viability assay was used to evaluate the anti-
proliferative activity of ISL towards both of the androgen 
receptor positive (LNCaP) and negative (DU-145) prostate cancer 
cell lines.  Fluorescence microscopy (FM) was used to observe 
the cell morphology of the cells.  To further understand the 
mechanism of action, flow cytometric and Western blot analysis 
were employed to investigate the effect on cell cycle, protein 
level of androgen receptor (AR) and prostate specific antigen 
(PSA).    Enzyme immunoassay (EIA) was used to determine the 
inhibitory activity against cyclooxgenase (COX).  
Results 
ISL exhibited a potent activity in suppressing prostate cancer cell 
proliferation.  The 50% inhibitory concentration (IC50) 
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and DU-145 respectively.  FM examination revealed an increased 
frequency of apoptosis in both cell lines.   At concentrations 
comparable to IC50 the flow cytometric data showed that ISL 
induced a G1 phase arrest in LNCaP (AR positive), while it 
blocked the cell cycle at G2M phase in DU-145 cells (AR 
negative). Western blot analysis further indicated ISL caused a 
down regulation of AR and PSA protein expression. The anti-
inflammatory property of ISL was found to be directly associated 
with its strong inhibition on COX activity, with an IC50 of 10.6 
µM for COX2.    
Conclusion 
Recent studies by various investigators confirmed the important 
role of AR and COX in controlling prostate cancer progression 
and metastasis.  The fact that ISL is a COX inhibitor and an AR 
modulator makes it a potential candidate for prostate cancer 
chemo preventive agent. Further investigation on its molecular 
mechanism and possible clinical benefit are warranted. 
 
 
Prostate cancer stem cells 
Anne T Collins, Steven D Bryce, Katy Hyde, *Michael J Stower, 
Norman J Maitland  
YCR Cancer Research Unit, Department of Biology, University 
of York, York YO10 5DD *Department of Urology, York 
District Hospital, York 
 
It is important to recognize that solid tumours are more than just 
a clonal expansion of mutant cells, but are instead heterogeneous 
and structurally complex.   
In this larger framework, tumour progression can be considered a 
developmental process in which a complex multicellular organ 
forms from rare tumour-initiating stem cells and evolving 
interactions with the microenvironment.  In order to study these 
rare tumour-initiating cells we have identified markers present on 
normal stem cells that are also present on prostate cancer cells.   
The HEA+/CD44+,21hi/CD133+ cells, selected from a series of 
primary and metastatic prostate cancers (n= 27; Gleason 5-6 (6), 
Gleason 7 (16), Gleason 8-10 (5) proliferate extensively in vitro, 
and comprise of 0.01% of the tumour population. The phenotype, 
HEA+/CD44+,21hi/CD133+ are clonogenic in soft agar, unlike 
their more differentiated progeny. The cancer cells display stem 
cell-like properties in that they are capable of generating new 
clones containing additional stem cells, as well as regenerating 
phenotypically mixed populations of non-clonogenic cells present 
in the original tumours 
Therefore, if the initiating cell is indeed the stem cell, therapies 
that are more specifically directed at cancer stem cells should 
result in more durable responses for primary as well as metastatic 
disease.   
 
 
Longitudinal changes in bone mineral density in advanced 
prostate cancer patients treated with androgen ablation or 
anti- androgen hormonal therapy and testosterone recovery 
following cessation of LH-RH analogues 
Wadhwa VK, Weston R, Hussain A, Parr NJ. 
Arrowe Park Hospital, Wirral, UK 
 
Introduction  
Androgen ablation with LH-RH analogues decrease serum 
testosterone levels and hence bone mineral density (BMD). They 
have been associated with accelerated bone loss and osteoporosis. 
An alternative is the anti-androgen bicalutamide which acts at the 
androgen receptor. Our aim was to study the effects of these 2 
treatments on the BMD of selected groups of patients. In an 
attempt to reduce further demineralization, patients found to be 
osteoporotic while receiving LH-RH analogues were converted to 
anti-androgen monotherapy.  
Materials and Methods  
367 men (mean age 73years, range 53-93) with prostate cancer 
requiring hormone manipulation were prospectively followed 
from Oct 1999 to Aug 2004. BMD of the forearm was measured 
by dual energy X-ray absorptiometry (DEXA) prior to hormone 
therapy and annually thereafter. Osteoporotic patients (t-score≤-
2.5) were commenced on bicalutamide. Osteopenic (t-score -1.0 
to -2.4) and normal (t-score>-1.0) patients were treated with LH-
RH analogues.15 osteoporotic patients receiving ≥12 months of 
LH-RH analogue were converted to anti- angrogen monotherapy. 
PSA and total testosterone were monitored at 3 monthly intervals.  
Results  
Osteoporosis was found in 42% of men with newly diagnosed 
prostate cancer prior to hormones. The osteoporotic group 
(n=155) did not show a significant change in BMD. (t-score at 
baseline -3.54;year1 -3.64; year2 -3.52; year3 -3.64; year4 -3.78). 
The osteopenic group (n=140) showed a statistically significant 
decrease in BMD, with 60% developing osteoporosis after 2 
years on LH-RH analogues. (t-score at baseline -1.72; year1 -
2.02; year2 -2.59; year3 -2.69; year4 -2.94). The normal BMD 
patients (n=72) also showed a significant decrease in BMD. (t-
score at baseline -0.25; year1 -0.58; year2 -0.83 ;year3 -1.28; 
year4 -1.52). 
All 15 patients converted to Bicalutamide demonstrated some 
testosterone recovery. Mean duration to initial detectable 
testosterone was 12.8 months(range6-22). Only 6 achieved a 
normal testosterone level after a mean of 17.5 months (range 14-
30).   
Conclusion  
Our data showed that patients treated with androgen ablation 
showed a significant decrease in BMD whereas those on anti-
androgen therapy maintained their BMD. We would advocate the 
routine assessment of BMD prior to hormone manipulation and 
surveillance thereafter to identify osteoporosis. This can be 
factored into the decision making process regarding the choice of 
androgen deprivation therapy.  
As regards patients already on LH-RH analogues, following 
cessation of these, testosterone levels continue to be suppressed. 
Conversion to anti-androgen does not offer a significant benefit 
and we would suggest studies of alternative therapies such as 
bisphosphonates.  
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